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The occurrence of Alzheimer’s disease (AD) is expected to quadruple by 2050. 
Currently, there is no treatment that cures or prevents the disease, thereby 
highlighting the necessity of developing a prophylactic and/or restorative therapeutic. 
Secreted amyloid precursor protein alpha (sAPPα) elicits neuroprotection, 
neurotrophism and enhances neuroplasticity, and so is an ideal candidate for 
development as an AD therapeutic. A number of membrane bound receptors for 
sAPPα have been suggested, however they have not been definitively validated. 
Furthermore, whether sAPPα is internalised upon binding is uncertain.  
This study aimed to express, purify, functionally validate and analyse cell surface 
binding of the fluorescent tagged sAPPα, EGFPsAPPα, and a number similarly tagged 
variant constructs of sAPPα. Enhanced green fluorescent protein (EGFP) was 
conjugated to the N-terminus of sAPPα, sAPPβ and sAPPα variants Δ602-612, Δ608-
612, K612A and RER328AAA to create a databank of variants which in the future could 
be used to investigate the critical active regions of sAPPα. The internal tripeptide motif 
(RER328) and the final C-terminal residues of sAPPα (595-612) have been proposed to 
be important in the protein’s function. As GFP is a large molecule, a variety of methods 
were used to assess that EGFPsAPPα maintained the functional properties of sAPPα. 
Glucose starved SH-SY5Y cells displayed an 18% increase in cell viability when 
incubated with EGFPsAPPα (10 nM) under optimised conditions, mirroring sAPPα’s 
neuroprotective capacity. EGFPsAPPα matched sAPPα’s ability to enhance long-term 
potentiation (LTP) in rat hippocampal slices, thereby validating that sAPPα function 
is not structurally perturbed by having EGFP conjugated at the N-terminus. Some 
evidence was obtained that these neuroprotective and LTP enhancing properties are 
due to EGFPsAPPα interacting with the plasma membrane. Total internal reflection 
fluorescence microscopy (TIRFM) analysis displayed single EGFPsAPPα molecules 
binding to the cell surface of SY-SY5Y cells. 
ii 
 
This study therefore supports the theory of sAPPα initiating its functions by binding 
to the cell surfaces, but rapid internalisation has not been excluded and is suggested 
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1.1 Alzheimer’s disease: A growing problem 
1.1.1 A problem and a solution 
Alzheimer’s disease (AD) is a neurodegenerative condition where atrophy of the brain 
promotes memory loss in afflicted patients. Microscopic examination of AD brains 
reveals an abundance of insoluble amyloid beta (Aβ) plaques and tangles of 
hyperphosphorylated tau, however the underlying mechanism of their neurotoxicity 
remains uncertain.  
Currently there is no early diagnosis of AD before onset of clinical symptoms or 
effective therapy once the symptoms are recognised. Secreted amyloid precursor 
protein alpha (sAPPα) is a naturally occurring protein expressed in the brain and other 
tissues of many species, and it provides promise as a protective therapeutic against 
AD. 
sAPPα conveys neuroprotective and neurotrophic properties, but how it elicits these 
actions remains unclear. A number of cell membrane or intracellular proteins have 
been nominated as being interacting partners but the receptor remains unidentified. 
Furthermore, it is not clear whether sAPPα is internalised to promote its effects 
intracellularly. This project focuses on the biology of how sAPPα’s signalling is 
initiated. 
1.1.2 Incidence rates 
Dementia encompasses a wide range of symptoms associated with a decline in 
memory and other cognitive deficits that are severe enough to reduce a person’s ability 
to perform everyday activities (Becker et al., 1988). AD is the most prominent form of 
dementia, accounting for 60-80% of cases (Association, 2013). In New Zealand the most 
recent dementia economic impact report in 2012 documents 48,182 New Zealanders in 
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2011 being diagnosed with dementia, AD accounting for ~35,000 cases (Economics, 
2012). The incidence of AD is expected to quadruple by the year 2050, emphasising the 
need for a prognostic diagnosis and for effective prophylactic therapeutics to be 
developed (Brookmeyer et al., 2007). 
1.1.3 Disease progression and economic impact 
Prior to a clinical diagnosis of patients having AD, neuropsychological investigation 
can detect mild cognitive impairments such as impairment in processing new 
information, an inability to plan, and difficulty in accessing semantic memory. This 
mild cognitive impairment may progress into classic dementia, which is characterised 
by impairments in learning and memory. Non-cognitive processes are also heavily 
affected during the moderate phase of AD, where a patient exhibits disturbances of 
perception and behaviour. Patients are completely reliant on caregivers during the late 
phase, and have major difficulties with verbal language as well as experiencing large 
muscle mass loss (Association, 2016; Förstl & Kurz, 1999; Jahn, 2013).  
Hence not only is there a debilitating loss in the quality of life for the individual 
patient, but also AD results in a broad substantive societal economic burden of health 
and social costs. In 2011, the total financial cost of dementia in New Zealand was 
estimated to be ~$1 billion (Economics, 2012).  
1.2 AD pathophysiology 
1.2.1 Macroscopic observations of AD brains 
The presence of reduced brain thickness in AD-vulnerable cortical regions are first 
expressed in presymptomatic individuals who harbour AD-like cerebrospinal fluid 
(CSF) molecular profiles (Lehmann et al., 2013; Sabuncu et al., 2011; Tarawneh et al., 
2015). These regions of interest include the entorhinal cortex, the temporal cortex, the 
lateral temporal cortex, the inferior parietal cortex, the inferior parietal sulcus, the 
posterior cingulate cortex, and the inferior frontal cortex (Möller et al., 2013). 
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Hippocampal volume is significantly reduced in symptomatic individuals and 
correlates with concurrent cognitive decline (Barnes et al., 2009; La Joie et al., 2013; 
Wisse et al., 2014). Figure 1.1 is a schematic diagram representing a cross-section of a 
post mortem healthy brain vs a post mortem AD brain. The profound neuronal loss 
seems to occur mainly in cholinergic neurons (Davies & Maloney, 1976; Grothe, 
Heinsen, & Teipel, 2013; Parent et al., 2013; Whitehouse et al., 1982). End stage 
neuroanatomy is characterised by widespread neuronal loss in regions causing the AD 
symptoms (Walsh & Selkoe, 2004). 
1.2.2 Current AD therapeutics 
In order to combat this loss of cholinergic neurons, cholinomimetics and cholinesterase 
inhibitors have been designed,(Craig, Hong, & McDonald, 2011; Erkinjuntti et al., 2002; 
Terry & Buccafusco, 2003). These however do not substantially halt the progression of 
the disease or restore the memory loss caused by AD. An alternative approach has 
been to use NMDA-receptor antagonists to combat glutamatergic excitotoxicity, an 
area that has been extensively researched in AD (Hynd, Scott, & Dodd, 2004). The 
NMDA receptor antagonist, memantine, reduces the effects of AD-induced deficits in 
long-term potentiation (LTP) and learned behaviour, and has been suggested as a 
combination therapeutic with cholinesterase inhibitors (Klyubin et al., 2011; Parsons 
et al., 2013). However, the use of memantine also inhibits LTP and spatial memory, 
therefore it is not the ideal candidate for an AD therapeutic. 
1.2.3 Micropathophysiological hallmarks 
Alois Alzheimer, the young doctor responsible for the discovery of AD, encountered 
his first case of the disease on November the 26th, 1901. For eight months, Auguste D 
had been developing progressive memory loss and changes in her personality. On 
April 8th 1906, Auguste died and her brain was sent to Dr Alzheimer for post-mortem 
analysis. Under microscopic examination, Dr Alzheimer found strongly stained 
intracellular fibrils as well as aggregated plaques scattered throughout the cerebral 
cortex (Dahm, 2006). These findings, novel at the time, are now recognised as classic, 
embodying the two leading hypotheses in AD progression; neurofibrillary tangle 
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(NFT) formations (Brion, 1998; Okamura et al., 2014) and amyloid beta (Aβ) plaque 
deposition (Figure. 1.1) (Hardy & Selkoe, 2002; D. J. Selkoe & Hardy, 2016). 
Figure 1.1 – Neuropathological hallmarks in an AD brain 
Comparison of an AD brain to a normal brain. The presence of amyloid-beta (Aβ) plaques and 
neurofibrillary tangles are thought to be involved with the neuronal loss in AD sufferers. Brain image 
was reused with permission from the BrightFocus® Foundation 2000. Plaques and tangles image re-used 
with permission from the Washington University School of Medicine. 
1.2.4 Amyloid beta hypothesis 
The extracellularly located plaques identified by Alzheimer were found to consist of a 
compacted core of amyloid filaments, composed of the peptide Aβ (D. Selkoe, 1994). 
At low concentrations Aβ in its monomeric form promotes neurotrophism of 
hippocampal neurons in vitro (Whitson, Selkoe, & Cotman, 1989; Yankner, Duffy, & 
Kirschner, 1990). Furthermore, Aβ antibodies and antisense mRNA to APP have been 
shown to have negative impacts on learning and memory in the T-maze foot shock 
avoidance test (Morley & Farr, 2012), a test that specifically measures a rodents left-
right discrimination and spatial memory.. 
Monomeric Aβ has the capacity to form soluble oligomers that have been found in 
buffer-soluble fractions of AD brains (McLean et al., 1999). These soluble oligomers, 
rather than monomers or the insoluble plaques, reduce neuronal viability (Dahlgren 
et al., 2002), inhibit hippocampal long-term potentiation (LTP) in vivo (Walsh et al., 
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2002) and induce N-methyl-D-aspartate subtype glutamate receptor (NMDAR) 
mediated synapse excitotoxicity and dysfunction (Tu et al., 2014). This implies that the 
extracellular amyloid plaques are only hallmarks of AD and not the causative agent 
(Shanker et al., 2008). 
1.3 The amyloid precursor protein (APP) 
1.3.1 APP superfamily 
APP, the precursor protein to sAPPα and Aβ, is part of a protein superfamily 
consisting of APP itself and amyloid precursor-like proteins (APLP) 
(Niederwolfsgruber et al., 1998). APP can be expressed as a number of isoforms, either 
APP563, APP751 and APP770 or APP695 which lacks the Kunitz-type protease inhibitor 
domain (KPI) (Tanzi et al., 1988). APP expression is highest in neuronal cells, with the 
APP695 isoform being the predominant isoform (Forloni et al., 1992; Tanaka et al., 1989). 
The physiological function of this family of proteins remains unclear, however the 
protein homology suggests conservation for a functional purpose. All members of the 
family encode for type-1 transmembrane proteins with a large extracellular domain, 
however APP is the only protein to contain the Aβ sequence.  
Figure 1.2 – APP695 domains and structural 
findings 
(A): Schematic representation of human holo-APP695. 
Arrows indicate where α-, β- and γ-secretase cleavage 
occurs. (B): Specific domains within APP can be 
broadly categorised into 2 domains, E1 and E2. E1 
consists of a growth factor-like domain (GFLD) and 
copper binding domain. E2 consists of the 
neuroprotective RERMS sequence and majority of the central APP domain (CAPPD). The red spheres 
represent N-glycosylation points in the carbohydrate domain. Adjacent to E2 is the juxtamembrane 
region (JMR) which contains the majority of the Aβ sequence (yellow), followed by the APP intracellular 
domain (AICD). The KPI is present in APP751 and APP770 but is absent in APP695. (C): Known structures 
of APP domains as found through NMR and X-Ray crystallography. This figure was reused with 
permission from the corresponding author of (Reinhard et al., 2012). 
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1.3.2 APP trafficking 
APP is transferred on synthesis to the endoplasmic reticulum (ER) and is trafficked to 
the plasma membrane (PM). During transit APP is exposed to multiple post-
translational modifications (PTMs) including N- and O- glycosylation (Weidemann et 
al., 1989), phosphorylation (F. Liu et al., 2003), tyrosine sulphation (Schubert et al., 
1989) and palmitoylation (Bhattacharyya, Barren, & Kovacs, 2013). Only a small 
proportion of emerging APP molecules reach the PM (estimated at 10% based on APP 
overexpression in cultured cells), whereas the majority of APP at steady-state localises 
to the Golgi apparatus and trans-Golgi network (TGN). APP remains at the PM for a 
limited period of time before the peptide signal, GYENPTY, initiates low density 
lipoprotein receptor mediated internalisation (Lai, Sisodia, & Trowbridge, 1995; 
Marzolo & Bu, 2009). Following endocytosis, APP is transported to the endosomes, 
where it may be recycled back to the cell surface or more commonly is delivered to the 
lysosomes (Haass et al., 1992). 
Figure 1.3 – Intracellular trafficking of APP 
(1): Nascent APP molecules (black bars) mature through the constitutive secretory pathway. (2): APP 
reaches the cell surface and is rapidly internalised. (3): Mature APP is sorted through endocytic 
organelles and is either recycled back to the cell surface or undergoes lysosomal degradation. Figure 
was reused with permission from the corresponding author of (Thinakaran et al, 2008). 
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1.3.3 APP proteolytic processing 
Regulated intermembrane proteolysis (RIP) is a process where a membrane spanning 
protein, in this case APP, undergoes two consecutive cleavages. One cleavage 
occurring in the external ectodomain and the other in the membrane spanning domain. 
This results in the release of a small peptide and a larger endodomain fragment (Brown 
et al., 2000; Lichtenthaler & Steiner, 2007). Three major proteases are involved in the 
proteolytic processing of APP, these include α, β and γ secretases. There are two major 
APP proteolytic processing pathways, the amyloidogenic and the non-amyloidogenic 
pathway. A novel η-secretase cleavage pathway has also been identified (Willem et al., 
2015). 
1.3.3.1 Amyloidogenic pathway 
Aβ is generated in this pathway by cleavage at two sites within APP by β- and γ-
secretase. β-secretase cleaves APP between Met596 and Asp597 (Y. Li et al., 2006), 
shedding a large soluble protein (sAPPβ) and generating an APP C-terminal fragment 
(βCTF; Figure 1.4). Gamma-secretase cleavage occurs within βCTFs membrane 
spanning domain, liberating the small Aβ peptide. Beta-secretase 1 (BACE1) is a 
metallo-proteinase that catalyses amyloidogenic cleavage at the β-site of APP. 
In this amyloidogenic pathway, γ-secretase activity at the membrane releases the APP 
intracellular domain (AICD) into the cytosol. This has been proposed to be involved 
in nuclear signalling and will be discussed later (Beckett et al., 2012).  
1.3.3.2 Non-amyloidogenic pathway 
The α-secretase disintegrin and metalloproteinase 10 (ADAM10) acts by cleaving APP 
at a site that is in the middle of the Aβ sequence and prevents Aβ generation (Esch et 
al., 1990). This processing step produces the membrane spanning αCTF and liberates 
the large ectodomain as a soluble fragment (sAPPα). As discussed later, sAPPα 
exhibits neurotrophic and neuroprotective properties, and is the protein of interest in 
this study. Further processing by γ-secretase within the membrane spanning region of 
αCTF releases the small 3 kDa fragment called p3 and the AICD peptide (Figure 1.4).  
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If cleavage by α and β secretases were to occur in the same cellular compartment, then 
the mutually exclusive pathways would compete with each other directly. But as 
discussed later, ADAM10 and BACE1 processing of APP is believed to occur in 
separate subcellular compartments, therefore secretases indirectly compete for APP 
processing (Jiang et al., 2014). Indeed moderate overexpression of ADAM10 in the 
mouse brain increased sAPPα formation, decreased Aβ generation and halted plaque 
deposition, supporting the theory of competitive APP processing, whether direct or 
indirect (Postina et al., 2004). 
1.3.3.3 η-secretase cleavage of APP 
Recently it has been discovered that APP can also be cleaved by another membrane 
bound matrix metalloproteinase, MT5-MMP (Willem et al., 2015). This is referred to as 
η-secretase and cleaves primarily at residues 504-505 of APP695, releasing sAPPη 
(Figure 1.4). C-terminal fragments (CTFs) generated from this cleavage can also 
undergo further processing by α- or β-secretases to form Aη-α and Aη-β respectively. 
Aη-α incubation in ex vivo hippocampal slices decreases LTP in a similar fashion as Aβ 
(Shankar et al., 2008).  
1.3.4 Subcellular sites of APP processing 
The various secretases involved in APP processing have different specific pHs at 
which they function optimally. As APP is trafficked through multiple subcellular 
compartments (detailed above) and where it is being processed will favour certain 
products depending on the local pH. 
1.3.4.1 Subcellular sites of α-secretase mediated APP processing 
Catalytically active ADAM10 is predominantly found at the cell surface on the PM and 
acts as a membrane localised sheddase (Seals & Courtneidge, 2003). It can also act as a 
vesicle-based protease and has previously been co-localised with the Golgi marker 
GM-130 (Gutwein et al., 2003). Activation of protein kinase C enhances the secretion 
of sAPPα by releasing secretory vesicles from the TGN to the PM that contain either 
APP or ADAM10 (Thinakaran & Koo, 2008). 
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Figure 1.4 α-, β-, γ- and η- secretase proteolytic processing of APP  
Proteolytic processing of APP by η-, β-, α- and γ-secretases. The non-amyloidogenic pathway 
(highlighted in blue) involves APP cleavage by α-secretase (ADAM10) to produce sAPPα. The 
competing amyloidogenic pathway (highlighted in red) involves β-secretase cleavage of APP to 
produce sAPPβ and C99. Successive processing of C99 by γ-secretase generates the neurotoxic Aβ 
peptide. The novel η-secretase cleavage of APP (highlighted in yellow) produces sAPPη. ADAM10 





1.3.4.2 Subcellular sites of β-secretase mediated APP processing 
BACE1 is initially synthesised at the ER as a catalytically inactive propeptide. 
Propeptide cleavage and multiple PTMs occur before full maturation and trafficking 
to the cell surface (Benjannet et al., 2001; Capell et al., 2000). The C-terminal domain of 
BACE1 contains a di-leucine motif which is involved in its internalisation (Pastorino 
et al., 2002). Once internalised it is transported to the endosome, where because of its 
low pH optimum, it is most active (Vassar et al., 1999). This suggests that β secretase 
cleavage that releases the APP C-terminal fragment containing an intact Aβ sequence 
is likely to occur at the intracellular endosomal/lysosomal transport and degradation 
pathways (X. Zhang & Song, 2013). 
1.3.4.3 Subcellular sites of γ-secretase mediated processing  
The γ-secretase complex consists of four subunits. One of these, Presenilin (PS) 
contains two critical aspartyl residues that form part of the catalytic aspartyl protease 
domain (Wolfe et al., 1999). Another subunit, nicastrin (NCT), is not catalytically active 
itself but promotes the maturation and proper trafficking of the other γ-secretase 
components (Y.-w. Zhang et al., 2005). Anterior pharynx defective -1 (APH-1), a 
protein originally identified in the Notch signalling pathway in C. elegans, is involved 
in regulating cell surface localisation of NCT (Goutte et al., 2002). Lastly presilin 
enhancer 2 (Pen-2) is involved in the endoproteolytic processing of PS and conferring 
activity to the γ-secretase complex (Takasugi et al., 2003). All four of these components 
are sufficient and necessary for γ-secretase activity (Edbauer et al., 2003). 
Aβ generation was initially believed to occur at the PM. However, many studies have 
now found that PS largely exists in the ER. This phenomenon was termed as the 
“spatial paradox” of γ-secretase activity (Annaert & De Strooper, 1999). As reviewed 
by Dries & Yu (2008), γ-secretase components can be divided into two pools based on 
where they have been found. Immature forms of γ-secretase components are found in 
intracellular membranes while active complex, constituting between 6-7% of total γ-
secretase, are found at the PM (Dries & Yu, 2008). Further supporting this, GFP tagged 
C99 was found to be cleaved by γ-secretase at the PM. 
11 
 
By blocking selective transport steps, Kaether et al (2006) demonstrated that γ-
secretase does not cleave its substrate at the ER, the Golgi, the TGN or secretory 
vesicles. Furthermore, inhibition of endocytosis did not restrict GFP-AICD production, 
suggesting that γ-secretase is active specifically both within the PM and the endosome. 
Further research revealed the production of Aβ in early endosomes, followed by 
packaging in multivesicular bodies (MVBs) and release into the extracellular space 
(Rajendran et al., 2006). The generation of Aβ in the endosome and other 
compartments with an acidic pH is unsurprising as γ-secretase was found, like β-
secretase, to have a low pH optimum of 4.5, with little activity at pH 7 (Pasternak, 
Callahan, & Mahuran, 2004). 
1.4 Function of full length APP 
Full length APP has been extensively researched but its functions still remain 
undefined (Deyts, Thinakaran, & Parent, 2016). As illustrated in figure 1.2, functional 
sites in APP have been mapped, including metal binding, extracellular matrix binding 
and neurotrophic domains. The following section aims to describe the role of APP in 
brain growth and protection. 
1.4.1. Neural and synapto-trophic evidence of APP 
Fibroblast cells have been shown to grow poorly when producing less APP mRNA 
after exposure to APP antisense cDNA (Saitoh et al., 1989). This phenotypic outcome 
is restored when growth media is supplemented with sAPPα. Furthermore, in vivo 
administration of sAPPα improves behavioural outcomes in rats, reducing 
hippocampal neuronal loss and axonal injury following severe, diffuse traumatic brain 
injury in rats (Thornton et al., 2006). sAPPα knock-in also rescues APP/APLP2 double 




A large body of evidence also supports the trophic function of APP in synapses. 
Intraocullar administration of siRNA targeting APP reduces the amount of newly 
synthesised and axonally transported APP in rats in vivo (Herard et al., 2006). This 
markedly reduces the visual stimulus-induced synaptic activity of the superior 
colliculus. Furthermore, dendrites in APP -/- mice exhibit a reduction in density, apical 
length and arborisation (Tyan et al., 2012).  
The importance of the APP family is also evident within neuromuscular junctions 
(NMJ). Double mutant mice expressing sAPPα knockin (KI) and APLP1 KO have both 
pre- and postsynaptic structural aberrations, resulting in reduced grip strength and 
impaired locomotor activity (Caldwell et al., 2013). These studies implicate the role of 
the APP family in normal central nervous system (CNS) and peripheral nervous 
system (PNS) development and maintenance, and explain why combinatory KOs of 
the APP family often lead to post-natal lethality. 
Collectively, these observations suggest a neurotrophic role for the extracellular 
domain of APP. 
1.4.2 APP in neurogenesis, synaptogenesis and neuronal migration 
It has been claimed that APP is involved in stem-cell proliferation and differentiation 
(Reinhard, Hébert, & De Strooper, 2005). Neural stem/progenitor cells (NSPCs) 
derived from APP overexpressing mice proliferate more frequently than control 
strains. NSPCs derived from APP KO mice display a clear reduction in proliferation 
rates in comparison to their control strains (Y. Hu et al., 2013). However, other 
researchers have found either a reduction in neurogenesis (Naumann et al., 2010) or 
no effect of APP on neuro-proliferation (Yetman & Jankowsky, 2013).  
Y. Hu et al (2013) proposed that APP may also play a role in regulating the 
differentiation of NSPCs. NSPCs from APP overexpressing mice were more likely to 




Multiple studies have established that APP is involved in neurite outgrowth. Blocking 
APP expression inhibits axon and dendrite outgrowth in embryonic cortical neurons 
growing in vitro (Allinquant et al., 1995). Knock down of APP in rodents with shRNA 
revealed that NSPCs were unable to migrate correctly to their target area. cDNAs 
encoding APP, APLP1 or APLP2 fully rescued the shRNA-mediated migration defect.  
During periods of development, APP is highly expressed in pre- and post-synaptic 
sites, and correlate with increased levels of synaptogenesis (Z. Wang et al., 2009). It is 
therefore believed that APP is involved in the creation and maintenance of paired 
synapses. This theory is supported by APP being able to promote cell-cell adhesion, 
which is hypothesised to be through trans-dimerisation of the molecule in the presence 
of heparin (Dahms et al., 2010; Soba et al., 2005). 
Synapse integrity is strongly affected by APP KO. Mice display a large amount of 
neurological detriments such as reduced grip strength, hypersensitivity to seizures, 
altered locomotor activity and impaired spatial learning (Ring et al., 2007). Deficits in 
neurogenesis and synaptogenesis may be why APP/APLP2 double KO experience 
post-natal lethality (P. Wang et al., 2005). 
1.4.3 APP in neuroplasticity 
Synaptic plasticity, in the form of LTP and long-term depression (LTD), provide the 
basis for most models of learning and memory. Both activation of α-amino-3-hydroxy-
5-methyl-isoxale-4-propionic acid subtype glutamate receptors (AMPARs) and 




The GluR2 subunit of AMPARs is known to control Ca2+ influx and therefore was 
hypothesised to be a tight regulator of LTP (Isaac, Ashby, & McBain, 2007). Mice 
lacking GluR2 show markedly enhanced LTP (Jia et al., 1996). Overexpression of APP 
not only upregulates GluR2 in AMPARs (K. J. Lee et al., 2010), but also stimulates the 
trafficking of NR2A- and NR2B containing NMDARs to the cell surface (Cousins et al., 
2009; Hoe et al., 2009). This suggests that APP along with its homologues is crucial for 
neuroplasticity and therefore memory and learning (Weyer et al., 2011). 
1.5 APP as a receptor 
The idea that APP functions as a receptor has gained momentum due to structural 
similarities with type-1 transmembrane receptors and the discovery of putative 
ligands. The following section will review experimental findings that support this 
concept. 
1.5.1 Receptor-like structural resemblance of APP 
All members of the APP family contain positively charged heparin binding domains 
and therefore can bind negatively charged molecules such as heparin. The first heparin 
binding domain located within the growth-factor like domain (GFLD) contains 3 
disulphide bridges linked between β-sheets. This domain displays structural 
similarities to ligand receptor sites in other growth factors and receptor-like proteins 
(Deyts et al., 2016). Another HBD within the membrane-proximal E2-domain is able to 
bind to membrane bound heparin sulphate proteo-glycans (HSPGs). These HSPGs act 
as low affinity co-receptors to enhance the binding affinity of APP to putative ligands 
(Reinhard et al., 2013). Synthetic peptides homologous to the heparin binding domain 
inhibited heparin binding and reduced the effect of APP on neurite outgrowth (Small 





1.5.2 Homo- and heterodimerisation of APP 
Homo and heterodimerisation is characteristic of many type-1 transmembrane domain 
receptors. Specific sequences within APPs E1 domain have been found to form the 
major interacting interface for homodimerisation and heterodimerisation with APLPs 
(Baumkötter et al., 2012; Soba et al., 2005). Structural analysis of APP revealed that 
dimerisation can occur through both of the extracellular E1 and E2 domains. This is 
suggested to be involved in facilitating synapse formation (Baumkötter et al., 2014). 
Anti-parallel dimerisation is also possible between monomers located on different 
cells, highlighting the potential functional implications in cell-to-cell adhesion and 
signalling (Y. Wang & Ha, 2004). 
The transmembrane region (TMR) of APP695 contains three consecutive GxxxG motifs 
that encompass residues 621-633 and are often found to mediate transmembrane helix-
helix interactions (Senes, Engel, & DeGrado, 2004). These motifs facilitate APP695 
homodimerisation (L. M. Munter et al., 2007), APLP heterodimerisation (Kaden et al., 
2009; L.-M. Munter et al., 2010) and interaction with BRI2, a protein associated with 
British and Danish dementia (Fotinopoulou et al., 2005; Matsuda et al., 2005). Secretase 
binding sites may be sterically hindered upon dimerisation, diminishing the rate of 
ectodomain shedding and therefore Aβ production (Matsuda et al., 2008). 
1.5.3 APP-mediated cell signalling 
Lipid rafts consist of cholesterol and sphingolipids and are subdomains of the PM. 
These rafts are enriched in signalling proteins and are implicated in vesicular traffic 
(Foster, de Hoog, & Mann, 2003). APP can be co-localised with these lipid rafts and its 
C-terminal domain interacts with the heterotrimeric G protein subunit Gαs. This in 
turn activates an adenylate cyclase/cAMP/PKA-dependent signalling cascade (Deyts 
et al.). The APP-CTF also interacts with the GαO providing evidence for APP as 
functioning analogously to a G-protein coupled receptor (Brouillet et al., 1999).  
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1.5.4 – Summary of APP function 
APP therefore seems to be not only a precursor protein to the neurotoxic Aβ and other 
neurotrophic proteins, but may be involved in other functions such as cell adhesion, 
growth promotion and receptor mediated cell signalling. The structure and 
dimerisation capabilities of the ectodomain support its receptor-like qualities. 
Figure 1.5 – Structural similarities to receptors and dimerisation of APP and APLPs. 
APP770 and its two mammalian homologues, APLP1 and APLP2. Conserved domains between APP and 
APLPs include E1 and E2 domains, acidic and Kunitz protease inhibitor domains, juxtamembrane 
region (JMR), intracellular phosphorylation and G-protein binding sites, and the YENPTY 
internalisation signal sequence. Putative ligands may bind to the high affinity heparin binding domain 
(HBD) in the E1 domain with help of the low affinity HBD located in E2 acting as a co-receptor. Cis-
homo- and cis-heterodimerisation can occur across these HBDs. Trans-homodimerisation across cells 
may be involved in cell adhesion and synapse maintenance. The GxxxG motif in the transmembrane 
region (TMR) allows for helix-helix interactions between proteins with similar sequences. This may alter 
the APP and APLP processing due to proteolytic sites being sterically hindered. This figure was re-used 
with permission from the corresponding author of (Deyts et al., 2013).  
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1.6 Function of APP proteolytic fragments 
1.6.1 – Physiological role of sAPPβ 
sAPP has only an extra 16 C-terminal amino-acids compared with sAPP and 
therefore both proteins are inferred to share many functions. Surprisingly, sAPPβ has 
~100 fold reduced neuroprotective potential, highlighting the importance of the C-
terminal region specific to sAPPα (Furukawa, Barger, et al., 1996). Moreover, both 
sAPPα and sAPPβ induce similar increases in axonal outgrowth (Chasseigneaux et al., 
2011). However, this effect is seen more efficiently with sAPPα as elongation is 
induced at lower concentrations.  
Deprivation of nerve growth factor (NGF) was found to trigger BACE1 cleavage of 
APP generating more sAPPand therefore more Aβ, which resulted in apoptotic 
death of PC12 cells (Matrone et al., 2008). sAPPβ was shown to interact with death 
receptor 6, which, upon binding, led to the activation of caspase 6. This non-classical 
effector was found to be involved in the apoptotic pathway of developmental axonal 
degeneration (Nikolaev et al., 2009). Surprisingly, sAPPβ also induces rapid neural 
differentiation in human embryonic stem cells more efficiently than sAPPα (Freude et 
al., 2011). Dysregulation of sAPPβ production could therefore contribute to the 
pathophysiology of AD. 
1.6.2 – Physiological role of Aβ 
While the current understanding is that neurotoxic Aβ oligomers are formed from the 
self-association of Aβ42 monomers, the function of monomeric Aβ has not been 
definitively determined. The presence of Aβ in a healthy brain and CSF suggests it has 
a physiological role (Shoji & Kanai, 2001). Under insulin deprivation, synthetic Aβ 
monomers have been shown to support the survival of premature neurons as well as 
protect against mature neuron excitotoxicity (Maria Laura Giuffrida et al., 2009). 
Further demonstrated by this group, the KLVFF sequence retained the neuroprotective 
properties of full length Aβ42 through activation of insulin growth factor-I receptors 
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(IGF-IRs) (Maria L Giuffrida et al., 2015). Activation of IGF-Irs control uptake of 
glucose in neurons through translocation of glucose transporters to the cell surface. 
Different isoforms of Aβ also have alternative effects on NPC differentiation; Aβ40 
drives neuronal differentiation while Aβ42 drives differentiation towards astrocyte 
lineage (Chen & Dong, 2009). High neuronal activity promotes Aβ generation and 
secretion, while in turn Aβ selectively depresses excitatory synaptic transmission 
(Kamenetz et al., 2003). Neuronal electrical activity may therefore modulate APP 
trafficking so that high activity promotes endocytosis and BACE1-mediated cleavage 
in the endosome/recycling compartments. Aβ could therefore play a physiological role 
in quenching neuronal hyperactivity through negative feedback loops. 
As indicated earlier, the predominant hypothesis behind Aβ induced toxicity is that 
they form soluble oligomers in the extracellular space. These oligomers inhibit NMDA-
mediated synaptic transmission and ultimately lead to diminished spine density and 
synapse loss (D. J. Selkoe, 2000). Oligomers isolated from the cerebral cortex of AD 
brains potently inhibit LTP, enhance LTD and reduce spine density in normal rodent 
hippocampi (Shankar et al., 2008). The observed alterations in synaptic plasticity were 
dependent on metabotropic glutamate and NMDA receptors. Insoluble amyloid 
plaques did not inhibit LTP unless solubilised to release Aβ dimers. These findings 
further support the idea that insoluble Aβ plaques are simply an insoluble endpoint 
in the change in physical state of A molecules. 
The cellular prion protein (PRPc) has been identified as a key factor in Aβ oligomer-
mediated synaptic dysfunction. Anti-PRP antibodies prevents Aβ oligomers from 
binding to PRP and as a result rescue synaptic plasticity in mice hippocampal slices 
(Laurén et al., 2009). 
1.6.3 – Physiological role of AICD 
AICD can have multiple lengths due to the numerous γ-secretase and caspase 3 
cleavage sites (Kim et al., 2003). As with Notch signalling, AICD contains the 
consensus motif YENPTY that is thought to be crucial for complex formation with Fe65 
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and histone acetyltransferase Tip60; the complex being known as AFT (Ando et al., 
2001). Fe65 binds to the C-terminal domain of APP and is transported to the nuclei 
where it can dock with Tip60. AFT can then bind to DNA binding domains such as 
Gal4 and LexA, thereby stimulating the expression of the APP effector genes APP, 
BACE, Tip60, CSK3B and KAI1. This promotes APP production and processing into 
AICD, where AICD is able to further promote the production of itself through positive 
feedback pathways (Cao & Südhof, 2001; von Rotz et al., 2004). Binding of Fe65 is 
dependent on AICD’s phosphorylation state, as phosphorylation or amino acid 
substitution at Thr668 supresses the interaction of the two proteins (Nakaya & Suzuki, 
2006). 
Overexpression of AICD in mice leads to AD-characteristics, including tau 
hyperphosphorylation and aggregation, neurodegeneration and working memory 
deficits. The pathological features displayed in mice were proposed not to be due to 
AICD alone, and therefore AICD and Aβ may act together to potentiate AD (Ghosal et 
al., 2009). 
These findings indicate that the intracellular domain of APP is not just an 
internalisation sequence for full length APP, but cleaved AICD plays a role in 
regulating specific genes. Alterations in the levels of nuclear AICD may therefore 
contribute to AD pathophysiology. 
 1.6.4 – Physiological role of sAPPα 
The physiological functions of sAPPα are also poorly understood, but as with 
membrane bound APP, the soluble ectodomain fragment is generally believed to be 
neurotrophic.  
Aged rats exhibiting reduced CSF sAPPα levels display a decreased performance in a 
water maze (J. Anderson et al., 1999). This deficit in spatial memory can be restored 
with exogenously injected sAPPα (C. J. Taylor et al., 2008). AD sufferers commonly 
exhibit lowered amounts of sAPPα within CSF. There is a significant correlation 
between low levels of sAPPα and human performance in neuropsychological tests that 
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measure intelligence, verbal functions, visuo-spatial functions, memory and attention 
(Almkvist et al., 1997). This suggests that sAPPα’s neurotrophic capabilities are 
important in normal physiological function. 
Aβ causes an elevation of intracellular [Ca2+] and free radicals leading to neuronal loss. 
sAPPα can protect from Aβ-mediated neuronal injury as well as excitotoxicity and 
glucose deprivation (Furukawa, Sopher, et al., 1996; Mattson et al., 1993). 
Neuroprotection is believed to be mediated through heparin binding sites located 
within sAPPα’s growth factor-like domains (GFLD) (Corrigan et al., 2011; Corrigan et 
al., 2014), and may occur through disruption of APP cis-homodimers (Gralle, Botelho, 
& Wouters, 2009).  
Mice performing learning tasks involving short and long term memory show 
increased memory-enhancing effects upon intracerebroventricular administration of 
sAPPα (Meziane et al., 1998). Intrahippocampal infusion of anti-sAPPα antibodies 
reduced hippocampal LTP by 50%. In a dose-dependent manner, recombinant sAPPα 
infusion increased LTP via NMDAR-mediated currents. TAPI-1, an α-secretase 
inhibitor, shows a potent decrease in NMDAR-mediated currents, LTP and an 
inhibition in spatial memory. These physiological abnormalities and memory deficits 
were restored with exogenous application of recombinant sAPPα (C. J. Taylor et al., 
2008).  
Using gene therapy, one study overexpressed sAPPα in APP/PS1ΔE9 AD model mice 
and investigated structural, electrophysiological and behavioural effects (Fol et al., 
2016). Mice with pre-existing AD micropathophysiological hallmarks and behaviour 
showed restored synaptic plasticity, spine density and spatial memory. Furthermore, 
a significant reduction in neurotoxic soluble Aβ oligomers was demonstrated. 
Many other studies have investigated the neurotrophic properties of sAPPα. 
Overexpression of ADAM10 displayed a significantly increased density of cholinergic, 
glutamatergic and GABAergic presynaptic bouton densities. Exogenous infusion of 
sAPPα led to a similar increase in synaptogenesis, supporting that the observed 
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changes were due to an increase in sAPPα secretion (Bell et al., 2008). Other studies 
have also reported observing neurite outgrowth in cultured cells that were either 
transfected with, or had exogenously applied sAPPα or sAPPα fragments (Gakhar‐
Koppole et al., 2008; Ohsawa, Takamura, & Kohsaka, 1997; Qiu et al., 1995). sAPPα 
and sAPPβ are believed to mediate its neurotrophic effects through interaction with 
P75 neurotrophin receptor (P75NTR) as sAPPα is unable to promote neurite outgrowth 
when P75NTR is knocked down (Hasebe et al., 2013) 
One of the earliest studies to document the positive effects of sAPPα was done by 
Ninomiya et al. (1993). Here, they applied a synthetic peptide of five amino acids, 
RERMS (APP328-332) and found it could promote the growth of fibroblasts. 
Recombinant sAPPα lacking this domain did not promote fibroblast cell growth, 
suggesting that this is the biologically active domain. Other studies have also reported 
sAPPα evoked NPC proliferation (Ohsawa et al., 1999). Further treatment with sAPPα 
also promotes NPC differentiation towards an astrocytic lineage (Baratchi et al., 2012).  
A number of studies have been published investigating the effects of sAPPα on gene 
regulation. Initial studies in pancreatic cell lines demonstrated that the addition of 
sAPPα (16 nM) induced a 2-fold change in gene expression with 59 overexpressed and 
130 underexpressed genes identified. These genes were part of clusters including: 
oncogenes and transcription factors, DNA helicases, pharmacologic mediators and 
p53 antagonists (Hansel et al., 2005). 
More recently members from our group have investigated the sAPPα-associated gene 
expression profiles in rat organotypic slice cultures exposed to 1 nM sAPPα (Ryan et 
al., 2013). They found that sAPPα rapidly regulates gene expression through multiple 
transcriptional regulatory mechanisms. A rapid but transient upregulation of 
inducible transcription factors (AP-1 complex & EGR1) was seen in slices following a 
15 min sAPPα incubation. These transcription factors control cell proliferation, 
survival and programmed cell death (Karin, Liu, & Zandi, 1997; Thiel & Cibelli, 2002).  
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Transcription factor NF-κB was consistently regulated over all time points measured; 
15 min, 2 h and 24 h. This is consistent with past research suggesting that sAPPα 
enhances expression of NF-κB and ultimately affects the regulation of gene expression. 
A correlation has been seen between the sAPPα facilitated induction of κB-dependent 
transcription with induction of TNF-β and I-κBα/MAD3 antisense, both of which are 
neuroprotective (S. W. Barger & Mattson, 1996). This implies that sAPPα’s ability to 
protect neurons from oxidative damage and excitotoxicity are in part due to regulating 
the gene expression profile. Interestingly, NF-κB expression has influence on the 
amount of Aβ expressed, and vice versa. During physiological conditions, NF-κB 
restricts Aβ production to maintain homeostatic concentrations, however during 
pathophysiological conditions NF-κB may participate in a positive feedback loop to 
generate more Aβ (Chami et al., 2012).  
Hence, these experiments have highlighted sAPPα’s involvement in regulating gene 
control. It would also seem that gene products regulated by sAPPα are also under tight 
regulation by Aβ. Whether this is because of the shared peptide sequences between 
the two molecules is uncertain and therefore more research needs to be undertaken to 
investigate their gene regulatory effects. 
Unexpectedly, sAPPα may also have oncogenic properties if concentrations are higher 
than the physiological range. The androgen receptor transcription factor, which is 
widely known to regulate genes involved in prostate cancer pathophysiology, 
upregulates APP as a primary target (Takayama et al., 2009). APP immunoreactivity 
in prostate cancer LNCaP cells correlated with poor prognosis in human patients. 
Overexpression of APP or sAPPα further accelerated the growth of these tumour cells 
in culture, while APP knockdown repressed cell proliferation. Similarly, high levels of 
sAPPα have been detected in pancreatic cancer cells both in vivo and in vitro (Hansel 
et al., 2003). Inhibition of sAPPα signalling by anti-sAPPα antibodies reduced cellular 
proliferation. Therefore, it plausible that APP and sAPPα may be supporting 
proliferation of cancer cells through its GFLD. 
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In summary, sAPPα seems to exhibit most of the physiological traits of APP. In light 
of all sAPPα’s positive effects, it seems plausible that sAPPα may be of use as a 
precursor to a therapeutic agent to combat Alzheimer’s disease. However, caution 
should be taken with the observation that high concentrations may lead to unregulated 
cell growth.  
1.6.5 – Mechanisms of sAPPα function 
Although the described functions of sAPPα are known, the underlying mechanisms of 
these properties are poorly understood. Multiple studies have reported the activation 
of mitogen activated protein kinase (MAPK)/extracellular signal-regulated kinase 
(ERK) in response to sAPPα (Gakhar‐Koppole et al., 2008; Greenberg & Kosik, 1995; 
Rohe et al., 2008). These kinases become activated upon binding of extracellular 
ligands to growth factor receptors and is paired with neurite elongation following 
neural stimulation. Activation of phosphatidylinositol-3 kinase, Akt kinase, and 
p42/p44 MAPKs have also been implicated in sAPPα mediated neurotrophic and 
neuroprotective mechanisms (Cheng et al., 2002).  
Holo-APP and G-protein mediated signalling was necessary for sAPPα-induced 
activation of the above kinases (Milosch et al., 2014). Supporting this notion, sAPPα 
was found to only stimulate neurite extension in the presence of APP. However, the 
outgrowth enhancing effects of sAPPα are inhibited by blocking antibodies to Integrin 
β1 (Itgβ1), a membrane bound receptor known for its neurite extending properties 
(Tomaselli et al., 1993, Young-Pearse, 2008). As APP co-localises with Itgβ1 at substrate 
contact sites, it is possible that sAPPα promotes neurite extension through disruption 
of the Itgβ1-APP interaction (Yamazaki, Koo, & Selkoe, 1997). This also further 
supports the theory of an interaction between sAPPα and membrane bound APP 
through trans-homodimerisation. 
As described above, sAPPα exhibits a number of properties that would be considered 
beneficial for a cellular environment. A number of studies have claimed indications of 
the binding of sAPPα to cells in a number of cell lines, however the membrane partners 
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and their requirement for sAPPα’s multiple functions still remains unclear 
(Chasseigneaux & Allinquant, 2012; Hoffmann et al., 1999). 
Binding of sAPPα to the cell surface suggests for interaction with membrane bound 
receptors. Indeed, there have been multiple studies reporting on these membrane-
localised interactions. As previously described, sAPPα and p75NTR have been co-
immunoprecipitated in vitro and co-localised in COS-7 cells (Hasebe et al., 2013). This 
interaction promoted neurite outgrowth in mouse cortical neurons, an effect that was 
abolished with p75NTR siRNA-mediated knockdown. 
S. W. Barger et al. (1995) investigated the excitoprotective effects of sAPPα and its’ role 
in neuronal calcium signalling. sAPPα rapidly decreased intracellular Ca2+ 
concentrations, an effect that was dependent on cGMP content. Upon sAPPα 
application, cGMP content increased in cultured hippocampal neurons. Inhibition of a 
cGMP-dependent kinase completely blocked the Ca2+ regulating and excitoprotective 
effects of sAPPα. Later, the same group found that sAPPα induced increase in cGMP 
was promoted through an interaction between sAPPα and a membrane-associated 
guanylate cyclase (S. Barger & Mattson, 1995).  
As mentioned previously, sAPPα binds to HSPGs located at the cell surfaces (Reinhard 
et al., 2013). In comparison to CHO cells, CHO-667 cells, a cell line deficient in HSPGs, 
displayed a 10-fold reduction in sAPPα cell surface binding, supporting the hypothesis 
of HSPGs being an interacting partner with sAPPα. Interestingly, despite the complete 
lack of HSPGs, sAPPα still displayed cell surface binding to CHO-667 cells, indicative 
for the existence of another sAPPα receptor.  
The neuronal sorting proteins, sorLA and sortilin, are known to mediate ligand 
internalisation at the PM (Hu et al., 2010; Nielsen et al., 2007; Nielsen et al., 2001). APP 
has been shown to interact with these proteins (Andersen et al., 2005; Spoelgen et al., 
2006; Yang et al., 2013) via the E2 domain, which is also present in sAPPα (Gustafsen 
et al., 2013). Gustafsen et al. (2013) further found that internalisation of fluorophore 
tagged sAPPα was enhanced upon transfection of HEK293T cells with sorLA or 
25 
 
sortilin. Furthermore, sAPPα internalised by sortilin was transported to vesicular-like 
structures widespread throughout the cell. These vesicles also expressed the lysosomal 
marker, LAMP-1, indicating that sortilin targets sAPPα for lysosomal degradation. In 
contrast, sAPPα internalised by sorLA was transported to paranuclear regions where 
it may initiate gene regulating mechanisms. 
1.7 Research Aims 
The research undertaken in this study is but a small part of the overall research goal 
of the group to develop a therapeutic for AD. As previously described, sAPPα exhibits 
many promising, potentially therapeutic properties, for AD and other 
neuropathophysiological conditions. Although cell surface binding has been 
suggested in previous research, it is unclear which domains within sAPPα are 
important for such an interaction with PM receptors. Furthermore, it is unclear 
whether sAPPα is mediating its signalling through internalisation, translocation to the 
nucleus and binding to target DNA, or whether it remains in the extracellular space to 
target secondary messenger pathways.  
A construct has been designed in which the N-terminus of sAPPα has been fused with 
enhanced green fluorescent protein (EGFP). EGFP has an extinction coefficient twice 
that of wtGFP, resulting in a 6-fold increased brightness. This will be useful in 
detecting binding partners of low abundance (Patterson et al., 1997).  
This study specifically targets regions of sAPPα that are hypothesised to be involved 
in the function of the protein. The regions include the neurotrophic RER tripeptide 
motif, the specific C-terminal region of sAPPα, and the final residue of sAPPα, K612, 





This study’s aims were to: 
1. To produce HEK293T/14 cells stably transfected with EGFPsAPP gene variants. 
2. To express the proteins from the stably transfected cells in culture, and purify 
them after secretion into the culture media.  
3. To validate that conjugating EGFP to the N-terminus of sAPPα does not 
inactivate sAPPα. 
4. To track cellular interaction of EGFP-tagged sAPPα using fluorometric 




 Chapter 2 
 Materials and Methods 
In this section media and solutions are referred to by their generic name only. For a 
detailed description of the components within each solution and each medium refer to 
Appendix I. 
2.1 Approvals and conditions 
In this study the use of Genetically Modified Organisms (GMO) was performed under 
PC1 containment approved by the Environmental Risk Management Authority, New 
Zealand (ERMA. GMD101715). Cell culture was performed under PC2 containment 
with the approval from the Institutional Biological Safety Committee (IBSC, 
GMD101730). All animal work was performed in PC2 containment under the approval 
of Otago University animal ethics guidelines (Animals Ethics approval ET21/07). 
2.2 Molecular biology techniques 
2.2.1 Transformation of E.coli 
E.coli DH5α genotype: F-Φ80lacZΔM15, Δ(lacZYA-argF), U169, recA1, endA1, hsdR17(rk-
, mk+), deoR, thi-1, phoA, supE44, thi-1, gyrA96, relA1, λ- were used to amplify plasmid 
stocks (Table 2.1). The DH5α strain is known to transform with high efficiency and it 
has specific genomic mutations that eliminates/inactivates intracellular 
endonucleases, thus allowing target DNA to be produced without degradation (R. G. 
Taylor, Walker, & McInnes, 1993).  
DH5α stocks were thawed on ice for 15 min. Plasmid DNA (10 ng) was mixed with 
100 μL of DH5α cells, incubated at 42oC for 45 s and cooled on ice for 1-2 min. Cultures 
were then enriched by adding 900 μL of 2 x YT media and incubated with shaking at 
200 rpm in an Innova®40 incubator shaker (New Brunswick Scientific Co Inc, USA) at 
37oC for 45 min. Each culture (100 μL) was plated onto LB agar plates with ampicillin 
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(100 μg/μL) and incubated at 37oC overnight. Untransformed DH5α cells were used as 
a negative control in every experiment. 
Table 2.1: List of plasmids 
2.2.2 Isolation of plasmid DNA 
Bacterial clones containing desired DNA constructs were grown in 5 mL of LB medium 
with ampicillin (100 μg/mL) overnight at 37oC. Plasmid DNA was eluted into 50μL of 
EB buffer (10 mM TrisCl, pH 8.5) using the QIAprep® Spin Miniprep Kit (Qiagen, 
Germany) according to the manufacturer’s instructions. 
2.2.3 Measurement of nucleic acid and protein yields 
DNA concentrations were measured with a NanoDrop ND-1000 Spectrophotometer 
(NanoDrop Technologies, USA). The ‘Nucleic acid’ application module determines 
DNA concentration as well as the A260/280 ratio (sample purity) in 1 μL of sample. 
The NanoDrop was also used to quantify protein concentration from fractions 
collected post-final desalting or size exclusion chromatography (SEC). The ‘Protein 
A280’ application module determines protein concentration as well as the A260/280 
ratio (sample purity) in 2 μL of sample. 
2.2.4 Digestion as a diagnostic tool 
Plasmid DNA (1 μg) isolated from miniprep amplification was subjected to digestion 
with either or both EcoRI and HindIII (Roche-Boehringer, Mannheim, Germany). Each 
Plasmid name Description (for protein expression) 
pcDNA3.1D SP-GFP-sAPPalpha wildtype sAPPα-EGFP fusion 
pcDNA3.1D SP-GFP-sAPPbeta wildtype sAPPβ-EGFP fusion 
pcDNA3.1D SP-GFP-sAPPalpha K612A sAPPα K612A–EGFP fusion 
pcDNA3.1D SP-GFP-sAPPalpha Δ608-612 sAPPα Δ608-612–EGFP fusion 
pcDNA3.1D SP-GFP-sAPPalpha Δ602-612 sAPPα Δ602-612–EGFP fusion 
pcDNA3.1D SP-GFP-sAPPalpha RER329AAA sAPPα RER328AAA–EGFP fusion 
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restriction endonuclease (2.5 U) and reaction buffer (1x) was used in a 20 μL reaction. 
After incubation at 37oC for 2 h, 10 μL of the reaction mixture was analysed by gel 
electrophoresis (Section 2.2.5). Controls included undigested vector. 
2.2.5 Agarose gel electrophoresis 
Plasmid DNA and fragments generated from miniprep amplification or digestion by 
restriction endonucleases were analysed by agarose gel electrophoresis. DNA was 
mixed with 1 x DNA loading buffer before being loaded onto a 1% (w/v) agarose gel 
with 0.5 μg/mL ethidium bromide in 1 x TAE buffer. Also loaded was a DNA marker 
– 3 μL of 250 ng/μL λ DNA (Roche-Boehringer, Mannheim, Germany) digested with 
EcoRI and HindIII restriction endonucleases. Gels were subjected to constant voltage 
of 90 V for 60-90 min using a Bio-Rad POWERPAC 300 (Bio-Rad Laboratories Inc, 
USA) until the dye-front had migrated approximately two-thirds of the way down the 
gel. The gel was then viewed under UV light and photographed using a Gel Doc 
Imager (Bio-Rad Laboratories Inc, USA). 
2.3 Cell culture techniques 
Training in sterile and safety techniques was completed prior to cell culture work 
being performed. All glassware to be used in cell culture was baked at 2000C for 4 h to 
prevent culture contamination. Plastic ware was either purchased pre-packaged and 
sterile, or covered in aluminium foil and autoclaved. Glassware and plastic ware were 
kept separate for cell culture work to prevent contamination from outside sources. All 
cell culture work was performed in an ESCO Class II Type A2 Biological Safety Cabinet 
(Labculture®, USA). Before performing cell culture, all equipment and surfaces were 
cleansed with 70% (v/v) ethanol. Clean gloves and a dedicated cell culture lab coat 
were worn while working with cells. Cultures were checked daily using a Nikon 




2.3.1 Cell lines 
Four cell lines were used in this study, all obtained from the American Type Culture 
Collection (ATCC®, USA). These were Chinese Hamster Ovary (CHO), Human 
Embryonic Kidney 293T (HEK-293T), NTERA-2 (NT2) and SH-SY5Y cell lines.  
The CHO cell line (ATCC® reference number CCL-61) is generally used for therapeutic 
protein production and the investigation of epidermal growth factor receptor 
mutations (Ahsan et al., 2009; Jayapal et al., 2007). These cells were used in total 
internal reflection fluorescence microscopy (TIRFM) as they were the first cells that did 
not contain endogenous fluorescence. 
The second cell line was the HEK-293T/17 cell line (ATCC® reference number CRL-
11268). The original HEK cells were extracted from a healthy aborted foetus and 
transformed with sheared adenovirus 5 DNA. This cell line contains the SV40 Large 
T-Antigen, which allows for the episomal replication of transfected plasmids 
containing the SV40 origin of replication site (Graham et al., 1977). As the HEK-293T/17 
cell line divides rapidly and is easily transfectable, this cell line was used to produce 
the various EGFPsAPPα proteins and EGFPsAPPβ. 
The NT2 cell line (ATCC® reference number CRL-1973) is a clonally derived, 
pluripotent, human embryonal carcinoma cell line. These cells exhibit biochemical and 
developmental properties similar to the cells of early embryo development. NT2 cells 
are typically used in the studies of early human neurogenesis. These cells were used 
in TIRFM due to their neuronal-like properties (V. M.-y. Lee & Andrews, 1986). 
The human derived SH-SY5Y neuroblastoma cell line (ATCC® reference number CRL-
2266) was generated from a bone marrow biopsy of a metastatic neuroblastoma site. 
SH-SY5Y cells are neuronal-like cells with multiple neurites and therefore possess 
neuron-like characteristics. These cells were used in cell viability assays, flow 
cytometry, fluorescence microscopy, immunocytochemistry and TIRFM. 
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2.3.2 Growth of cells 
CHO cell lines were grown in Ham’s F-12K (Kaighn’s) Medium (Gibco® Invitrogen 
Corporation, USA) with low glucose (1.26 g/L), L-glutamine (2 mM) and sodium 
pyruvate (220 mg/L). Media was supplemented with 10% (v/v) foetal bovine serum 
(FBS, Gibco® Invitrogen Corporation, USA) and 1% (v/v) Penicillin Streptomycin 
solution (100x; Gibco® Invitrogen Corporation, USA). 
Both the HEK-293T/17 and NT2 cell lines were grown in Dulbecco’s modified Eagle’s 
medium (DMEM, Gibco® Invitrogen Corporation, USA) with high glucose (4.5 g/L), L-
glutamine (4 mM) and sodium pyruvate (110 mg/L). Media was supplemented with 
10% (v/v) FBS or non-supplemented, termed DMEM+ and DMEM- respectively. Media 
was further supplemented with 1% (v/v) Penicillin Streptomycin solution. 
SH-SY5Y cell lines were grown in a 1:1 mixture of Minimal Essential Medium α 
(MEMα, Gibco® Invitrogen Corporation, USA) and Ham’s F-12K (Kaighn’s) Medium. 
The MEMα used contained low glucose (1 g/L), L-glutamine (2 mM) and sodium 
pyruvate (110 mg/L). Media was supplemented with 10% (v/v) FBS and 1% (v/v) 
Penicillin Streptomycin solution. 
All cells were grown at 37oC in a 5% CO2 atmosphere using an incubator (Forma® Steri-
Cycle® CO2 incubator, Thermo Fisher Scientific Incorporated, USA). Medium was 
replaced at regular intervals (2-3 days) to keep cells in a nutrient rich and non-harmful 
environment. Cells were grown in either 50 mL (T25), 250 mL (T75) or 650 mL (T175) 





2.3.3 Storage of cells 
Cells were stored for long term preservation at a low passage number (passage 2-3). 
They were initially grown to 80-90% confluence in T75 flasks before being trypsinised 
(Section 2.3.5), pelleted by centrifugation (CL10 Centrifuge, Thermo Fisher Scientific 
Incorporated, USA) at 1000rpm for 4 min and re-suspended in 5 mL freezing medium 
containing 90% (v/v) FBS and 10% (v/v) DMSO. Cells were then transferred in 1 mL 
aliquots into cryo-tubes and stored at -80oC for short term storage, or transferred to 
liquid nitrogen for long term storage. 
2.3.4 Seeding cells from frozen stocks 
Frozen cell stocks were rapidly thawed in a 37oC water bath (SUB Aqua 12, Grant, UK) 
for 1 min. The aliquots were then taken up in pre-warmed medium (9 mL) and 
centrifuged at 1000rpm for 4 min. The freezing medium was then aspirated and the 
cell pellet was re-suspended in cell specific medium (5 mL, Section 2.3.2). Cells were 
then seeded in T25 flasks. 
2.3.5 Passaging of cells 
Cells were passaged when 80-90% confluent. This was to ensure there were enough 
cells for the next stage of seeding, as well as to avoid overcrowding of cells. Medium 
was aspirated and the cells were washed twice in 1 x PBS (PBS tablets, Oxoid Ltd., UK, 
dissolve 1 tablet in 100 mL). 0.05% (w/v) trypsin (1 mL, Gibco® Invitrogen Corporation, 
USA) was incubated with the cells for 4 min, to digest the proteins adhering the cells 
to the flask. Cell specific media (9 mL) was then added to stop the digestion and re-
suspend the cells. The cell suspension was centrifuged at 1000 rpm for 4 min and the 
supernatant was aspirated. The cell pellet was then re-suspended in cell specific media 
(12 mL, Section 2.3.2). CHO, NT2 and SH-SY5Y cells were aliquoted into T75 flasks, 
and HEK 293T/17 cells into either T75 or T175 flasks. Cells were maintained for 
between 15-20 passages before being discarded. SH-SY5Y cells have been known to 
spontaneously differentiate and lose neuronal characteristics if the passage number 
exceeds that of 20 (Monaghan et al., 2008). 
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2.3.6 Transfection of DNA 
HEK293T cells were grown up to 80% confluency in T75 flasks. The cells were then 
transfected with 1 μg of plasmid DNA (Table 2.1) using X-treme gene 9 DNA 
transfection reagent (Roche-Boehringer, Mannheim, Germany) at a ratio of 1:3. 
Selection of integrants was performed using 1000 μg/mL G418 for 21 days on the basis 
of results obtained from a G418 concentration optimisation experiment (Section 3.2.2). 
Stable integrants were pooled and were either cryo-preserved (Section 2.3.3) or grown 
(2.3.2) for protein production (Section 2.5). 
2.3.7 Flow cytometry and fluorescence activated cell sorting (FACS)  
FACS was performed on HEK293T/14 EGFPsAPPα Δ602-612 and RER328AAA stable 
cell lines, while flow cytometry was performed on EGFPsAPPα incubated SH-SY5Y 
cultures. Cells were grown in T75 flasks and were used for analysis when they were 
80% confluent. The media was aspirated and cells were washed twice in 1 x PBS. 0.05% 
Trypsin (1 mL) was incubated with the cells for 4 min and cells were re-suspended in 
cell-specific media (9 mL). The cell suspension was centrifuged at 1000 rpm for 4 min 
and then the supernatant was removed. The cell pellet was then re-suspended into a 
single cell suspension in 1 x PBS containing 2 mM EDTA (1 mM, Scharlau Chemie S.A., 
Spain) and 1% (v/v) FBS. An aliquot of 50% (v/v) trypan blue (0.4%) stained cell 
suspension (20 μL) was added to a hemocytometer (Weber Scientific, New Zealand). 
The number of viable cells was calculated using a Nikon Eclipse TS100 (Japan) 
microscope and the cell suspension was then adjusted to a concentration of 2 x 107 
cells/mL. Cells were sorted/analyzed based on EGFP expression/binding. 
If cells were to be collected afterwards for culturing, they were sorted with a FACS 
Aria (Becton-Dickinson, CA, USA). These cells were eluted into cell specific medium 
with 1% (v/v) antibiotic/antimycotic solution (Gibco, Invitrogen Corporation, CA, 
USA) and were re-seeded into a T75 flask. If the cells were to be discarded following 
flow cytometry analysis, they were sorted with a FACS Canto II (Becton-Dickinson, 
CA, USA). Non-transfected cells were used as a control to set the cut-off value for 
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background fluorescence. Data was analysed using the program FlowJo_V10 
(Treestar, Inc., San Carlos, CA). 
2.3.8 Seeding cells into 6, 24 and 96 well plates. 
When 80% confluency was achieved, cells were passaged (Section 2.3.5) and the cell 
pellet was re-suspended in 10 mL of cell-specific media. An aliquot of the cell 
suspension (20 μL) was added to a hemocytometer (Weber Scientific International Ltd, 
UK). The concentration of the cell suspension was adjusted to 5 x 105 cells/mL and the 
volume in each well was adjusted to either 2 mL, 500 μL or 100 μL for 6, 24 and 96 well 
plates respectively. Cells were incubated until they reached 80% confluency. 
2.3.9 Seeding cells onto 18 mm glass coverslips 
Glass coverslips (18 mm; Menzel Glaser, Braunschweig, Germany) were flame 
sterilised with 70% ethanol (v/v) and placed in a 6 well plate (one coverslip per well). 
When 80% confluency of cells was achieved, they were passaged (Section 2.3.5) and 
the cell pellet was re-suspended in 10 mL of cell-specific media. An aliquot of the cell 
suspension (20 μL) was added to a hemocytometer. Total cell number was calculated 
and the concentration of the cell suspension was adjusted to 5 x 105 cells/mL. Cells at 
this concentration were seeded onto each coverslip. Cells were incubated for 24 h at 
37oC prior to being used in TIRFM. 
2.3.10 Treating cells with sAPPα or EGFPsAPP variants 
Once target confluency of cells seeded into wells (Section 2.3.8) or coverslips (Section 
2.3.9) was reached, medium was aspirated and replaced with sAPPα or EGFPsAPP 
variant containing media at varying concentrations. Cells were analysed via flow 
cytometry (Section 2.3.7), fluorescence microscopy (Section 2.3.12) and TIRFM (Section 
2.3.13), were fixed with 4% (v/v) paraformaldehyde (PFA) for 10 min at room 






Cells without EGFPsAPPα were pre-washed in primary antibody (rabbit polyclonal 
anti-GFP antibody (ab290; Abcam, Cambridge, MA; 1:1000)) with immunobuffer (IB; 
Appendix I) for 1 h at room temperature to clean impure antibody preparations 
(Linterman et al., 2011). After EGFPsAPP incubation all cells were then incubated in 
primary antibody over night at 4oC. Cells were then washed 3 x in PBS plus 0.1% (v/v) 
Triton-X-100 (PBS-T). The secondary antibody (goat anti rabbit, Alexa Fluor®514 
conjugate (A-31558; Invitrogen, California, USA) was diluted in IB (1:10000), syringe 
filtered and incubated with cells for 2 h at room temperature on a shaker. Double 
stranded DNA (dsDNA) was stained with Hoechst 33342 (1:10,000; H3570, Thermo 
Fisher Scientific, Massachusetts, USA). Cells were then either visualised via 
fluorescent microscopy (Section 2.3.12) or stored at 4oC until required. A list of 
antibodies used in this study can be seen in Table 2.2. 
Table 2.2 – List of antibodies 
Primary Antibodies 
Product Source Working dilution Catalogue # Company 
Anti-α-tubulin Rabbit 1:6666 Ab4074 Abcam 
Anti-GFP Rabbit 1:1000 Ab290 Abcam 
Anti-N-term APP Rabbit 1:1000 A8697 Sigma Aldrich Inc 
Anti-Puromycin Mouse 1:1000 EQ0001 Kerafast 
 
Secondary Antibodies 
Product Source Working dilutions Catalogue # Company 
Anti-rabbit-HRP Goat 1:10000 A6154 Sigma Aldrich Inc 
IRDye 800CW anti-mouse Goat 1:15000 926-32350 Licor 
IRDye 680RD anti-rabbit Goat 1:15000 926-68071 Licor 




2.3.12 Conventional fluorescence microscopy 
Cells were viewed using an Olympus IX-71 inverted microscope and photographed 
with a 12.5 mega-pixel cooled Olympus DP71 digital camera. Differential Interference 
Contrast (DIC) images and fluorescent images were taken using an Olympus U-RFL-
T fluorescent light source with a WIBA filter block for GFP. 
2.3.13 Total internal reflection fluorescence microscopy (TIRFM) 
Single molecule detection of EGFPsAPP variants were achieved using an objective 
type TIRF microscope.  
Microscope set-up 
A hybrid TIRF microscope (IX-81+BX51; Olympus) was located at the Department of 
Physiology (University of Otago). The microscope was fitted with a 100 x Olympus 
TIRF objective, Zero Drift Compensation and a Hamamatsu 9100-13 EM CCD camera. 
Excitation of fluorophores were achieved through diode lasers (488nm; Spectra-
Physics, Santa Carla, CA), with a WIBA filter block for GFP. Cells seeded onto 
coverslips (Section 2.3.9) were secured in place in a sample chamber (Figure 2.1). 
(Kwakowsky, Potapov, & Ábrahám, 2013) details a theoretical and practical 
introduction for TIRFM on neuronal-like cell lines. 
Figure 2.1 TIRFM sample chamber. 
The coverslip is secured to the bottom of the 
aluminium base, the Perspex cone (white) is placed 
on top and the aluminium ring is screwed onto the 
top. This locks the coverslip in place and allows for 






At the microscope 
Cells were initially cultured in the Biochemistry Department (University of Otago), 
transported to the Physiology Department and placed in a 37oC incubator for 1 h to 
recover. Cells were then treated with EGFPsAPP variants (Section 2.3.10) and were 
recorded for 3000 frames in MetaMorph Premiere imaging software creating a stacked 
image. 
2.3.14 Single molecule identification data analysis 
Stacked images were analysed for the identification of single molecules using the 
program ImageJ (Abràmoff, Magalhães, & Ram, 2004). The lateral dynamics of EGFP 
was analysed to determine whether sAPPα binding occurred on SH-SY5Y cell 
membranes. Receptor binding and lateral dynamics on cell membranes have been 
described by (C. M. Anderson et al., 1992). Cell membranes were first defined by 
visualisation with visible light. Tracking of single molecules was achieved by a manual 
tracking ImageJ plugin designed by (Cordelières., 2005). Coordinates (xy) of single 
molecules were recorded by clicking on the structure of interest. Upon doing so the 
next image in the stacked appeared and xy coordinates for the structure of interest was 
again gathered. These steps were repeated until the structure of interest vanished from 
the field of view. 
2.3.15 Treating cells with TNF-alpha protease inhibitor I (TAPI-1) 
Inhibition of α-secretases was performed using TAPI-1 (50 μM, Peptides International, 
USA) by incubating SH-SY5Y cells for 24 h subsequent to the fluorescence microscopy 
(Section 2.3.12) or viability assay (Section 2.3.16 or 2.3.17). The TAPI-1 concentrations 
and incubations times used have previously been found to be effective in inhibiting 
the production of endogenous sAPPα production (Hogl et al., 2011) 
2.3.16 MTT cell viability assay 
The 3-(4,5 dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay was 
used as a means of indirectly testing for cell viability. It is a colorimetric assay that 
detects the conversion of MTT (a yellow salt) to its formazan (insoluble purple 
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crystals). The reduction of tetrazolium dye is dependent on NAD(P)H-dependent 
oxidoreductases, and therefore is reliant on cellular metabolic activity. If there is a 
decrease in cell viability, then there would be an expected decrease in production of 
formazan crystals. Cells seeded on a 96 well plate (Section 2.3.8) were incubated in 
TAPI-1 (Section 2.3.15). Cells were then treated with varying concentrations of sAPPα, 
EGFPsAPPα or a vehicle of 0.1 x PBS for 2 h. Recombinant proteins were diluted from 
stock solutions in 0.1 x PBS so that a final volume of 10 μL was added per well. This 
mixture was added to 90 μL of DMEM+ media/well to give desired protein 
concentrations. Following pre-treatment, DMEM+ media was aspirated and replaced 
with DMEM glucose free media (Gibco® Invitrogen Corporation, USA). Cells were 
then left to grow for a desired amount of time at 37oC. 
Two hours prior to the end of the assay, MTT was added (0.28 mg/mL). At the end of 
the assay, media was carefully removed from the wells using a syringe and needle, so 
that formazan crystals were not disrupted in the process. Formazan crystals were then 
solubilised in 50 μL of DMSO:EtOH (1:1) for 10 min at room temperature. Absorbance 
was measured at 562 nm using an ELx808® Ultra Micro Plate Reader (Bio-Tek 
Instruments Inc, USA). 
2.3.17 Resazurin cell viability assay 
The resazurin cell viability assay was used as an alternate option to the MTT cell 
viability assay as it has been reported to have higher sensitivity and is much easier to 
use (van Tonder, Joubert, & Cromarty, 2015). This viability assay detects the 
conversion of resazurin, a weakly fluorescent blue dye, into the pink coloured and 
highly fluorescent resofurin. Reduction of resazurin into resofurin occurs likely 
because of oxidative metabolism, but it is uncertain whether this occurs at the 
mitochondria, PM or in the medium as a chemical reaction (O'Brien et al., 2000). Cells 
were seeded on a 96 well plate (Section 2.3.8) and were incubated with TAPI-1 (Section 
2.3.15). Cells were then pre-treated with varying concentrations of sAPPα, 
EGFPsAPPα or a negative control of 0.1 x PBS (vehicle) for 2 h. Recombinant proteins 
were diluted from stock solutions in 0.1 x PBS so that a final volume of 10 μL was 
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added per well. This mixture was added to 90 μL of DMEM+ media/well to give 
desired protein concentrations. Following pre-treatment, DMEM+ media was 
aspirated and replaced with DMEM+ glucose free media (Gibco® Invitrogen 
Corporation, USA). Cells were then left to grow for a desired amount of time at 37oC. 
Three hours prior to the end of the assay, resazurin was added (0.03 mg/mL). A 
CLARIOstar (BMG Labtech) was used to excite fluorophores at 530nm in 96-well and 
measure at 590 nm. 
2.4 Animal techniques 
All experiments were outsourced to researchers with expertise in the following 
techniques. Jodi Morrissey performed hippocampal slice preparation and field 
potential electrophysiology. 
2.4.1 Animals 
All experiments were conducted on tissue prepared from male Sprague-Dawley rats 
(42-56 d) as previously described (Mockett et al., 2007). All experimental procedures 
were carried out under the approval by the University of Otago’s Animal Ethics 
Committee and in accord with New Zealand’s animal welfare legislation. 
2.4.2 Field potential electrophysiology 
Rats were deeply anaesthetised with ketamine (100 mg/kg, ip), and the brains removed 
and chilled in ice-cold oxygenated artificial cerebrospinal fluid aCSF for which sucrose 
was substituted for NaCl (composition in mM: sucrose 210, glucose 20, KCl 2.5, 
NaH2PO4 1.25, NaHCO3 26, CaCl2 0.5, MgCl2 3, pH 7.4 when gassed with 95% O2-5% 
CO2). Slices (400 μm) were subsequently prepared using a vibroslicer (Leica, VT1000), 
bathed in aCSF (1 ml/2 h/32°C) in 35 mm tissue culture dishes (five to six slices/dish) 
and held at interface in a static incubation chamber containing an oxygen-rich and 
humidified atmosphere. sAPPα, EGFPsAPPα and other drug treatments were 
subsequently bath-applied in fresh oxygenated and warmed aCSF for 30 min. 
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Transverse hippocampal slices (400 μm) were transferred to an oxygenated and 
humidified static incubation chamber where they were placed on Millicell culture 
plate inserts (Millipore, Billerica, MA, USA) in interface contact with aCSF and held at 
32 oC for at least 30 min to equilibrate.  The incubation chamber was then allowed to 
cool to room temperature and the slices held for a further 90 min. 
The aCSF for field recordings consisted of (in mM): NaCl 124, KCl 3.2, NaH2PO4 1.25, 
NaHCO3 26, CaCl2 2.5, MgCl2 1.3, D-glucose 10, and was equilibrated with carbogen 
(95% O2-5% CO2). Following 2 h recovery, slices were transferred to a recording 
chamber through which aCSF equilibrated with carbogen was superperfused 
continuously at a rate of 2 ml/min and maintained at a temperature of 32.5 oC. Baseline 
field excitatory postsynaptic potentials (fEPSPs) were elicited in area CA1 by 
stimulation of the Schaffer collateral-commissural pathway at 0.017 Hz (diphasic 
pulses, 0.1 ms half-wave duration) using a teflon-coated 50 μm tungsten wire 
monopolar electrode (A-M Systems Inc, Carlsborg, WA). Evoked responses were 
recorded with a glass microelectrode filled with aCSF (2-3 MΩ) and placed in stratum 
radiatum of area CA1. During periods of baseline recording the stimulation intensity 
was adjusted to elicit a fEPSP with an initial slope value of 40% of the maximum 
elicited when delivering 200 µA of current. Baseline stability was visually assessed 
immediately prior to bath-perfusion of the drugs and by linear regression at the 
conclusion of each experiment (Raymond et al, 2000). sAPPor EGFPsAPPα, was 
bath-applied by switching to an identical preheated and oxygenated aCSF solution 
that contained the compound of interest. Drugs were applied for 25 min before the 
tetanus and for 5 min after (ie., 30 min in total). Non-saturated LTP was induced by 
applying a “half” theta burst stimulus (0.5 TBS, 5 trains of 5 pulses at 100 Hz delivered 




2.5 Protein techniques 
2.5.1 Harvesting variant EGFPsAPP protein 
The justification for the design of variant EGFPsAPP is described in Section 3.1.1. The 
protocol for purifying out wildtype sAPPα was first described by Turner et al. (2007). 
Stably transfected HEK293T cell lines containing vectors coding for various 
EGFPsAPP were grown and transferred to progressively larger flasks by passaging 
(Section 2.3.5). Once T175 flasks reached 80% confluency, the protein production 
procedure commenced. DMEM+ was aspirated and replaced into flasks for 24 h to 
ensure optimal cell health. The fresh DMEM+ was then removed and cells were 
washed twice with 1 x PBS. Medium was then replaced with DMEM-, a critical step in 
EGFPsAPP subsequent purification as this removes excess unwanted proteins found 
in FBS. All EGFPsAPP variants expressed a secretion tag and so were secreted 
extracellularly into the medium. Medium was collected 4 d after incubation and 
centrifuged for 5 min at 1000 rpm to remove any cell debris. The supernatant was 
transferred to sterile centrifuge bottles containing PMSF (1 mM, Sigma, Australia) and 
EDTA (1 mM Scharlau Chemie, Spain), to protect against proteolysis, and was stored 
briefly at -20oC. After medium collection, the cells that were still viable were allowed 
to recover for 24h in fresh DMEM+ and then were re-used for repeated cycles of media 
collection. 
2.5.2 Ammonium sulphate precipitation 
Ammonium sulphate precipitation was used to precipitate EGFPsAPP variants from 
collected DMEM- media (Section 2.5.1). Ammonium sulphate was slowly added to the 
media at 70% saturation over 30 min at 4oC with constant stirring. The protein extract 
was then left to stir gently for an additional hour. The precipitated protein was then 
pelleted by centrifugation at 10,000 rpm for 40 min at 4oC with an Avanti® J-26 XP 
Centrifuge with a F14BCI-6x250y rotor (Beckman Coulter, USA). The supernatant was 
carefully removed and the pellet was re-suspended in 3mL of desalting buffer 




2.5.3 Desalting chromatography 
Desalting chromatography was use to remove residual amounts of ammonium 
sulphate from concentrated protein solutions (Section 2.5.2) or NaCl from fractions 
eluted using heparin affinity chromatography (Section 2.5.4). Samples from 
ammonium sulphate precipitation (1 mL) were desalted by injection through a 
HiTrap® (Amersham Biosciences, Sweden) desalting column attached to an ÄKTATM 
Purifier FPLC system (Amersham Biosciences, Sweden). Prior to heparin affinity 
chromatography (Section 2.5.4), fractions were eluted into desalting buffer (1 mL/min). 
Following heparin affinity chromatography, fractions were again desalted and eluted 
into 0.1 x PBS (1mL/min). Elution of proteins was monitored by absorbance at 280nm, 
and elution of salt was monitored with a conductivity meter. This enabled the accurate 
detection of the separation between protein and salt. Eluted fractions (1 mL) were 
collected with the Fraction Collector Frac-950 (Amersham Biosciences, Sweden). 
Collected fractions were then stored at -20oC until required 
2.5.4 Affinity chromatography 
Initial desalted fractions were purified using a 5 mL HiTrap® heparin column 
(Amersham Biosciences, Sweden) attached to an ÄKTA TM Purifier FPLC system 
(Amersham Biosciences, Sweden). Protein aliquots (5 mL) were injected through a 10 
mL loop into the column and allowed to bind. Excess desalting buffer was washed 
through the column until all unbound protein had been eluted. Bound protein was 
removed from the column by exposure to a NaCl gradient (0-90% over 80 min) in 
elution buffer (Appendix I). Eluted fractions were collected at a rate of 1mL/min and 
were collected in 1 mL fraction. Fractions were then tested for the presence and purity 
of EGFPsAPP variants by Colloidal Coomassie staining (Section 2.5.6) and 
immunoanalysis (Section 2.5.9) 
2.5.5 Size exclusion chromatography (SEC) 
Affinity purified fractions of interest containing contaminating proteins were further 
purified using a Superdex 200 10/300 GL column (GE Healthcare, UK) attached to an 
ÄKTA TM Purifier FPLC system (Amersham Biosciences, Sweden). Protein aliquots (0.5 
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mL) were eluted into 0.1 x PBS (1 mL/min) Elution of proteins was monitored by 
absorbance at 280m, and elution of salt was monitored with a conductivity meter. 
Eluted fractions were collected and EGFPsAPP variants were quantified against 
known sAPPα standards by immunoanalysis. 
2.5.6 SDS-PAGE 
EGFPsAPP fractions from the desalting, affinity and size exclusion chromatography 
were analysed using sodium dodecyl sulphate polyacrylamide gel electrophoresis 
(SDS-PAGE). Samples were subjected to separation by 10% (w/v) SDS-PAGE gels (30% 
acrylamide solution 37.5:1 acrylamide:bis-acrylamide (Bio-Rad Laboratories Inc., USA; 
Appendix I). Gels were prepared using the Mini-PROTEAN® 3 system (Bio-Rad 
Laboratories Inc., USA). Gels were overlaid with isopropanol (200 μL) to generate a 
flat interface. This was washed off and 10% (w/v) stacking gel was applied. Protein 
samples were mixed with 3x cracking buffer (10:7 ratio; Appendix I) containing 10% 
(v/v) β-mercaptoethanol (Sigma, Australia) and 10% (v/v) glycerol (Biolab, Australia). 
The samples were then heated to 960C for 10 min to denature proteins and 15 μL of the 
mixture was loaded. Broad Range SDS-PAGE Molecular Weight Standards (Bio-Rad 
Laboratories Inc., USA) were diluted to 0.1 μg/μL with cracking buffer, denatured and 
loaded onto each gel (10 μL). Gels were initially run at 120V using a Model 200/2.0 
Power Supply (Bio-Rad Laboratories Inc., USA), until the dye front passed the stacking 
gel. Then the gels were run at 200V for 1 h. Proteins were detected either by colloidal 
Coomassie (Section 2.5.6) or transferred to a membrane for Western immunoanalysis 
(Section 2.5.9). 
2.5.7 Colloidal Coomassie staining 
SDS-PAGE gels used for fractionating proteins (Section 2.5.5) were washed in fixative 
solution for 1 h to remove interfering compounds. Gels were then washed in ddH20 
for 2 x 10 min, and were stained in colloidal Coomassie stain overnight. Gels were then 
washed in ddH20 for 1 h, followed by 2 h in destaining solution (Appendix I). 
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2.5.8 Western transfer of proteins to nitrocellulose membranes 
Proteins were transferred from SDS-PAGE gels to Protran® nitrocellulose membrane 
(Schleicher & Scheull, Germany) for immunoanalysis. SDS-PAGE gels were placed 
adjacent to nitrocellulose membrane within a sandwich of 3MM filter paper 
(Whatman, UK) and sponges either side. The sandwich was soaked in transfer buffer 
(Appendix I) before being placed into a Mini Trans-Blot system (Bio-Rad Laboratories 
Inc., USA). Transfer of proteins to nitrocellulose membrane was carried out at 100 V 
for 1 h using a Model 200/2.0 Power Supply (Bio-Rad Laboratories Inc, USA). 
Transferred proteins were detected by placing the nitrocellulose membrane in 
Ponceau S (Acros Organics, USA) solution for 15 min. Membranes were rinsed with 
ddH2O, and the location of the marker bands were indicated with a pencil. Membranes 
were then blocked overnight at 40C in a solution of 1 x PBS with 0.1% (v/v) Tween 20 
(PBST) with 1% (w/v) skim milk powder (blocking solution), prior to the use in 
immunoanalysis. 
2.5.9 Dot blot hybridisation 
Known amounts of protein were applied to Protran ® nitrocellulose membranes 
(Schleicher & Scheull, Germany), allowed to dry, and then blocked in blocking solution 
for 2 h at 40C. Blots were incubated in primary antibody for 2 h, followed by 3 x 10 min 
washes in 1 x PBST. Blots were then incubated in secondary antibody for 1 h again in 
PBST for 3 x 10 min. 
2.5.10 Western immunoanalysis 
Blocked membranes were incubated with a primary antibody for 2 h at RT with gentle 
shaking (Platform STR8 shaking tray, Stuart Scientific, UK). Primary antibodies were 
diluted in blocking solution. Membranes were washed for 3 x 10 min in 1 x PBST with 
gentle rocking. Membranes were then incubated with secondary antibody for 1 h at 
RT with gentle rocking. Secondary antibody was diluted in 1 x PBST. Membranes were 
then washed again for 3 x 1 min in 1 x PBST with gentle rocking.  
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Enhanced chemiluminescence (ECL) was used for secondary antibodies with 
conjugated horse radish peroxidase (HRP). The membrane was soaked in 1 mL/10cm2 
of ECLTM Western Blotting Detection Reagents (GE Healthcare, UK) and proteins were 
viewed using the Fujifilm Intelligent Dark Box LAS-3000 Image Reader (Fukufilm 
Corporation, Japan) according to the manufacturer’s instructions.  
Blots containing secondary antibodies conjugated to fluorophores were visualised 
using an infrared scanner (Odyssey®Licor).  
2.5.11 BCA Assay 
The BCA assay is a colorimetric assay used to determine concentrations of protein in 
solution. This assay relies on the chelation of biocinchoninic acid with Cu+ to form an 
intense purple coloured product. A six-point standard curve with a range of 0-0.5 
mg/mL using bovine serum albumin (BSA) protein (Sigma-Aldrich Inc., USA) was 
generated by serial dilution. Each point of the standard curve was measured in 
triplicate. EGFPsAPP protein (25 μL) was incubated with 200 μL of BCA reagent (50:1 
ratio of BCA working reagents A and B, Sigma-Aldric Inc., USA) in a 96 well plate 
(Nunc, Thermo Fisher Scientific Incorporated, USA) for 30 min at 37oC. Absorbance 
values were measured at 562 nm using an Elx808TM Ultra Microplate Reader (Bio-Tek 
Instruments Inc, USA). These values were compare to the BSA standard curve to 





Purification of EGFPsAPP variants 
3.1 Experimental tools 
3.1.1 Context for design of sAPP variants 
sAPPα displays neurotrophic (Bell et al., 2008; Jin et al., 1994; Ohsawa et al., 1997; Qiu 
et al., 1995) growth promoting (Baratchi et al., 2012; Ninomiya et al., 1993; Ohsawa et 
al., 1999), neuroprotective (Furukawa, Sopher, et al., 1996; Y. Goodman & Mattson, 
1994; Mattson et al., 1993; Stein et al., 2004), gene regulating (Ryan et al., 2013) and 
memory enhancing (C. J. Taylor et al., 2008) properties. Specific regions within sAPPα 
have been implicated to be involved in these functions. sAPPβ, which lacks the final 
16 C-terminal residues found on sAPPα, has been shown to have a 100-fold lower 
neurotrophic efficacy (H. L. Li et al., 1997; Turner et al., 2003). Deletion variants lacking 
11 or 5 amino acids, sAPPα Δ602-612 and sAPPα Δ608-612, were made in this research 
group in order to determine whether all 16 amino acids were essential for the distinct 
functions of sAPPα, or whether it was due to specific residues within this sequence. 
A five amino acid sequence within sAPPα, Arg328-Ser332 (RERMS), has been shown to 
represent the active domain that promotes fibroblast growth (Ninomiya et al., 1993). 
Recent findings have shown that the isolated small palindromic tripeptide within this 
motif, RER, is able to mimic sAPPα’s promotion of LTP in Spraque-Dawley rat 
hippocampal slices (Morrissey, Tate, Hughes & Abraham – unpublished results). 
In order to determine whether the residues within the RER motif are important in 
initiating sAPPα’s signalling, the sAPPα variant RER328AAA was made. Earlier, MSc 
student Gary Morris made an AER variant that retained neuroprotective activity 
(Morris. G., 2011). Alanine scanning is a technique used to determine whether specific 
amino acids contribute to the structure or function of a given protein directly. As 
alanine is a small, neutral amino acid it is less likely to disrupt protein structure when 
being substituted for an amino acid in a protein, therefore loss of functional activity 
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can identify important residues and their side chains which are critical for this 
function.  
Previous studies by two students in the Tate group into the C-terminal 16 amino acids 
of sAPPα have investigated the importance of the final lysine residue of sAPPα. The 
sAPPα mutations K612V and K612A abolished its neuroprotective effects (Mukadam. 
A., 2009) and perturbed sAPPα-Aβ binding (Thomsen. M., 2012). 
In order to investigate which region/s of sAPPα play an important role in its initial 
signalling, constructs were developed containing an N-terminally conjugated 
EGFPsAPP variant fusion protein. A schematic diagram representing the selected 
variants is displayed in Figure 3.1. This chapter describes the expression, purification 
and quantification of EGFPsAPPα, EGFPsAPPβ, EGFPsAPPα Δ602-612, EGFPsAPPα 
Δ608-612, EGFPsAPPα RER328AAA and EGFPsAPPα K612A. 
Figure 3.1 – Schematic diagram of EGFPsAPP variants  
Each sAPP variant has an N-terminally conjugated EGFP. Blue represents regions of APP included in 
sAPPβ. Regions in red represent the C-terminal 16mer of sAPPα which is also part of the Aβ sequence. 
Regions in yellow represent specifically substituted residues. 
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3.2 Generation of stable cell lines 
3.2.1 Amplification of plasmid DNA 
DNA constructs containing EGFPsAPPα or mutated variants were designed and 
cloned by Dr Lucia Schoderböck. Construct stocks were amplified by transformation 
in E. coli for use in stable cell line generation. They were first digested and analysed 
via agarose gel electrophoresis to confirm the EGFPsAPPα, EGFPsAPPβ or mutant 
variant inserts were present in the isolated DNA. EcoRI and HindIII were used to drop 
out the EGFPsAPPα insert. An example is shown with EGFPsAPPα in Figure 3.1A. A 
schematic diagram of such an EGFPsAPPα inserted into the pcDNA3.1D vector 
backbone is presented in Figure 3.1B. 
The uncut plasmid displayed typically more than one band on the gel due to different 
physical forms of supercoiled circular DNA. EcoRI and HindIII have a single cut site 
within the plasmid, so digestion with either enzyme resulted in a linear 8103 bp form 
of the complete plasmid DNA. Digestion with both EcoRI and HindIII dropped the 
insert (2575 bp) out of the vector backbone (5528 bp). The concentration of amplified 
plasmid DNA was then 
determined by Nanodrop as 
shown in Table 3.1 
Figure 3.2 - Restriction digest 
of plasmid 11LS - 
EGFPsAPPα 
A: EGFPsAPPα construct incubated 
without (uncut) or with EcoRI, 
HindIII, or both restriction 
endonucleases. Marker; EcoR1 & 
HindIII digest of lambda DNA. 
B: Schematic diagram of the EGFP-





Table 3.1 – Amplified plasmid DNA 
 
3.2.2 G418 concentration optimisation 
The G418 concentration used in selection of stably transfected HEK293T cultures was 
determined based on the results of a G418 killing curve (Figure 3.3). Based on visual 
examination, the concentration of G418 that kills 100% of cells in 21 days was found to 
be 1000μg.mL-1. 
Figure 3.3 –G418 concentration optimisation for selection against non-transfected 
cells 
HEK293T cells were seeded at 1 x 106 cells/well into 6 well plates. Starting with no G418, each 
subsequent well increased in G418 concentration by 250 μg/mL until 1250 μg/mL. Cells were imaged 
under bright field at 21 days. 
Plasmid Construct Concentration (ng.μL-1) Yield (μg) 
11LS EGFPsAPPα 480 24 
12LS EGFPsAPPβ 521 26 
14LS EGFPsAPPα Δ602-612 357 18 
16LS EGFPsAPPα Δ608-612 436 22 
17LS EGFPsAPPα RER328AAA 450 23 
18LS EGFPsAPPα K612A 340 17 
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3.2.3 Transfection of HEK293T cells with purified plasmids 
HEK293T cells were transfected with each plasmid, selected for stable insertion by 
resistance to G418, and analysed for the apparent proportion of transfected to non-
transfected cells. This was achieved by viewing the cells for GFP fluorescence under a 
fluorescence microscope and therefore transfected cells needed to be expressing the 
fluorescent protein to score as a positive. Cell populations consisted mainly of 
fluorescing cells, suggesting that the transfection and selection of all variant stable cell 
lines had been successful (Figure 3.4 & 3.5). Small populations of non-fluorescent 
HEK293T cells were still resistant to selection by G418 with all variants. They may have 
integrated the vector into the genome, be expressing the resistance gene but not the 
EGFPsAPP variant. 
Figure 3.4 – HEK293T EGFPsAPPα and EGFPsAPPβ stable cell lines 
HEK293T cells were plated 24 h prior to transfection. Cells were stably integrated with EGFPsAPPα and 
EGFPsAPPβ constructs once reaching optimal confluency (70-90%). Stable cell lines were viewed under 





Figure 3.5 – HEK293T cultures expressing EGFPsAPPα variants 
HEK293T cells were plated 24 h prior to transfection. Once reaching optimal confluency (70-90%), cells were stably integrated with EGFPsAPPα Δ602-612, Δ608-612, 




3.3 Purification of EGFPsAPPα and EGFPsAPPβ 
3.3.1 EGFPsAPP variant isolation and purification overview 
All constructs contained the APP secretion signal, so the expressed proteins were 
secreted into extracellular cell media. After the cells underwent one round of media 
collection they were allowed to recover in serum positive media for 1 d before being 
subjected to another 4 d serum negative cycle. This cycling was repeated until the 
desired volume of medium containing secreted EGFPsAPP variant proteins had been 
collected. The purification protocol used was adapted from Turner et al. (2007).  
Figure 3.6-Strategy for EGFPsAPP variant isolation and purification 
Protocol for isolation and purification of EGFPsAPP variants from transfected HEK293T media. 
Stably transfected HEK293T cells are grown to 80% confluency 
 
Media replaced with fresh serum positive media for 1 day 
 
Cells washed and media replaced with serum –ve media 
 
Serum –ve media collected after 4 days 
 
Protein concentrated at 70% ammonium sulphate saturation 
 
Concentrated protein desalted 
 
Desalted protein purified via heparin binding affinity chromatography 
 
Purified proteins desalted 
 




3.3.2 Precipitation of EGFPsAPPα and EGFPsAPPβ protein from HEK293 media 
Ammonium sulphate precipitation is a salting out technique in which target protein 
can be concentrated and partially purified from crude media. At high salt 
concentrations, hydrophilic interactions between the target protein and water are 
disrupted. As a result, protein-protein interactions are favoured, proteins aggregate 
together and precipitate out of solution.  
While ammonium sulphate at 50% saturation precipitated most of the EGFPsAPPα 
and EGFPsAPPβ protein, without precipitating significant amounts of other 
contaminating protein, a 70% saturation was used in order to maximise yields (Figure. 
3.7) 
Figure 3.7-EGFPsAPPα and EGFPsAPPβ ammonium sulphate precipitation 
optimisation 
Proteins were precipitated from HEK293T cell media samples (1 mL) containing EGFPsAPPα or 
EGFPsAPPβ at increasing ammonium sulphate saturations. Insoluble proteins were pelleted by 
centrifugation, supernatant was transferred to another microcentrifuge tube and the next increment of 
ammonium sulphate was applied. Protein pellets were resuspended in 10 μL of 1 x PBS and were 
separated on a SDS-PAGE gel (10%). The region of target protein is indicated by the black arrow. 
3.3.3 EGFPsAPPα FPLC purification. 
sAPPα contains several heparin binding domains and therefore can be purified via a 




Salt is used to elute the target protein from the heparin affinity column. The 
concentrated protein was first desalted using a HiTrap® desalting column attached to 
the ÄKTATM FPLC system (Amersham Biosciences, Uppsala, Sweden). A clear 
separation was seen between the eluted A280 protein peaks and salt peaks (Figure 3.8A).  
The one-step heparin affinity purification protocol was first established by our group 
to purify wild-type sAPPα (Turner et al., 2007). The affinity of EGFPsAPPα for the 
heparin binding column becomes disrupted with increasing salt concentration and 
therefore the protein is eluted. Following desalting FPLC, protein containing fractions 
(A2 and A3 – see Figure 3.8A) were pooled and loaded onto a HiTrap® heparin column.  
WT-sAPPα had been previously found to elute at a salt concentration of 1.2 M. The 
heparin binding FPLC chromatogram for EGFPsAPPα can be seen in Figure 3.8B. As 
the A280 profiles for both WT-sAPPα and EGFPsAPPα were similar, EGFPsAPPα 
appeared to elute around this salt concentration. These fractions and other fractions 
with high A280 values were tested for the presence and purity of the target protein 
(Figure 3.9). 
Western analysis displayed 140 kDa bands in fractions C2-C6, confirming the presence 
of EGFPsAPPα within these fractions (Figure 3.9B). Colloidal Coomassie staining 
displayed little contaminating protein within these fractions, thereby demonstrating 
the purity of EGFPsAPPα (Figure 3.9A). Although fractions C6, C7 and C8 appeared 
to contain EGFPsAPPα as shown by the colloidal Coomassie stained gel, these bands 
did not appear on the Western blot, likely due to an incomplete Western transfer of 
protein. 
Like sAPPα, EGFPsAPPα eluted at 1.2 M NaCl as expected from the A280 profile (Figure 
3.8B). The NaCl used to elute EGFPsAPPα was removed by further desalting of 
individual fractions. A clear separation was seen between the protein elution peak and 




The relative mass of EGFPsAPPα was found to be ~140 kDa. This is consistent with the 
current literature as sAPPα with post-translational modifications (PTM) has a mass of 
~110 kDa, EGFP has a mass of 26.9 kDa, therefore giving a combined relative mass of 
136.9 kDa (Figure 3.9B). 
Figure 3.8 - FPLC purification of EGFPsAPPα  
(A): Initial desalting FPLC chromatogram of ammonium sulphate concentrated EGFPsAPPα. 
(B): Heparin binding affinity FPLC chromatogram of desalted EGFPsAPPα fractions. The black arrow 
indicates the elution peak of EGFPsAPPα. The red bar indicates fractions containing EGFPsAPPα, 
confirmed by immunoblotting. (C): Final desalting of heparin purified fraction C5. Blue line represents 
the A280, brown line represents the NaCl conductance (ms/cm). Dashed pink line represents the 
injection of sample into the FPLC system. 
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Figure 3.9 Purity of post heparin bound EGFPsAPPα fractions 
Heparin bound fractions were analyzed for the presence and purity of EGFPsAPPα by immunoblotting 
and colloidal Coomassie staining. (A): Colloidal Coomassie stained gel of post-heparin bound fractions 
of interest. (B): Western blot of post-heparin bound fractions of interest. Primary antibody = anti-N-
terminal APP. Secondary antibody = anti-rabbit HRP. Marker; Broad range protein marker. sAPPα; 
Purified sAPPα positive control. A13-C8; Heparin affinity-purified EGFPsAPPα fractions. 
3.3.4 Quantitative densitometry of EGFPsAPPα 
The relative concentration of purified EGFPsAPPα was determined by comparing 
against sAPPα standards of known concentrations. This was preferred to a classical 
BCA assay as gel analysis uses a 10-fold lower amount of EGFPsAPPα. The 
nomenclature used for quantification of purified EGFPsAPP variant fractions is 
described in Figure 3.10. Both purified fractions and standards were separated on a 
SDS-PAGE gel, transferred to a nitrocellulose membrane and immunoblotted (Figure 
3.11). Immunoanalysis detected several bands of lower Mr in purified fractions, 
suggesting some degradation of EGFPsAPPα. 
Band density was calculated by the software ImageJ. Density values of standards were 
then compared to density values of purified EGFPsAPPα. Yields of purified 





Figure 3.10 – Nomenclature used in EGFPsAPP variant quantification. 
C5 represents the fraction C5 collected from heparin affinity FPLC. This fraction is then subjected to a 
final desalt or SEC. A4 represents the fraction A4 eluted from subsequent final desalt or SEC 
purification. 
Figure 3.11 – Quantification of purified EGFPsAPPα 
Western blot comparing purified EGFPsAPPα to sAPPα standards of known concentration. Primary 
antibody = anti-N-terminal APP. Secondary antibody = anti-rabbit HRP. Marker; Broad range protein 
marker. sAPPα; Purified sAPPα positive control. C5A4-C8A7; final desalt purified EGFPsAPPα. 
Table 3.2 – Purified EGFPsAPPα yields 
  
Fraction C5A4 C5A5 C6A3 C6A4 C6A5 C7A3 C7A4 
Concentration (nM) 648 891 367 753 732 161 621 
Yield (μg) 89 122 50 105 102 22 87 
        
Fraction C7A5 C8A3 C8A4 C8A5 C8A6 C8A7  
Concentration (nM) 432 188 295 55 0 0  
Yield (μg) 60 26 40 7.5    
Fraction number from 
heparin affinity FPLC 
Fraction number from 




3.3.5 EGFPsAPPβ FPLC purification and yield quantification 
Using the same procedure as for EGFPsAPPα purification, concentrated EGFPsAPPβ 
was re-suspended in desalting buffer, ammonium sulphate removed by desalting 
FPLC, purified on a heparin affinity column, and then desalted again. The desalting 
procedure successfully separated protein from ammonium sulphate (Figure 3.12A). 
Initial desalted fractions A2 and A3 were purified with a heparin binding column, 
which produced a chromatogram with a similar A280 profile to that of EGFPsAPPα 
(Figure 3.12B). Fractions C12-D5 were subjected to immunoanalysis and colloidal 
Coomassie staining to determine the presence and purity of EGFPsAPPβ respectively 
(Figure 3.13). Immunoanalysis displayed dense ~135 kDa bands in heparin-affinity 
purified fractions C12-D4, confirming the presence of EGFPsAPPβ. Colloidal 
Coomassie staining displayed little contaminating protein, suggesting that these 
fractions were pure. 
Despite EGFPsAPPβ lacking the 16 C-terminal residues of EGFPsAPPα, the protein 
was still eluted from the heparin binding column at the same salt concentration. The 
EGFPsAPPβ containing fractions, C12-D4, were desalted and quantified via 
densitometry against sAPPα standards of known concentrations (Figure 3.14). 




Figure 3.12 – FPLC purification of EGFPsAPPβ 
(A): Initial desalting FPLC chromatogram of ammonium sulphate concentrated EGFPsAPPβ. (B): 
Heparin binding FPLC chromatogram of desalted EGFPsAPPβ fractions A2 & A3. Arrow indicated the 
expected elution region of EGFPsAPPβ. The red bar indicates the fractions tested for the purity and 
presence of EGFPsAPPβ (C): Final desalting of heparin purified EGFPsAPPβ fraction C13. Final 
desalted fractions A2 & A3 (1 mL) were stored at -80 Co. The blue line represents A280 absorbance. The 
brown line represents NaCl conductance. The dashed pink line represents the injection of sample into 
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Figure 3.13 – EGFPsAPPβ containing post-heparin binding fractions 
Heparin bound fractions were analyzed for the presence and purity of EGFPsAPPβ by colloidal 
Coomassie staining and immunoblotting. (A): Colloidal Coomassie stained gel of post-heparin bound 
fractions of interest. The arrow indicates the presence of EGFPsAPPβ. (B): Western blot of post-heparin 
bound fractions of interest. Primary antibody = anti-N-terminal APP. Secondary antibody = anti-rabbit 
HRP. Marker; Broad range protein marker. sAPPα; Purified sAPPα positive control. C12-D5; Heparin 
affinity-purified EGFPsAPPβ fractions. 
Figure 3.14 Purified EGFPsAPPβ yield quantification 
Western blot comparing purified EGFPsAPPβ to sAPPα standards of known concentration. Primary 
antibody = anti-N-terminal APP. Secondary antibody = anti-rabbit HRP. Marker; Broad range protein 





Table 3.3 – Purified EGFPsAPPβ yields 
3.4 Purification of EGFPsAPPα variants 
3.4.1 EGFPsAPPα Δ608-612 purification and yield quantification 
As EGFP at the N-terminus of sAPPα did not affect the purification of the fusion 
protein, it was inferred that EGFPsAPPα variants Δ602-612, Δ608-612, K612A and 
RER328AAA would likely be purified with the same simple procedure, providing 
changing these specific regions did not alter the heparin binding capacity. 
The heparin binding chromatogram for EGFPsAPPα Δ608-612 exhibited the well 
characterised final A280 peak that suggested it eluted in the typical fractions (Figure 
3.15A). Colloidal Coomassie gel staining of proteins in fractions C7-C10 displayed 
strongly stained bands around 136 kDa, suggesting they were EGFPsAPPα Δ608-612 
(Figure 3.15B).  
By contrast with the first purification, EGFPsAPPα Δ608-612 containing fractions were 
contaminated with non-target proteins. It was subsequently discovered that there was 
a fault with the FPLC pump system during this purification and the elution buffer did 
not produce a continuous salt gradient. This irregularity in buffer salinity may have 
affected the purification of EGFPsAPPα Δ608-612 as there were several protein 
contaminants within fractions of interest. Size exclusion chromatography (SEC) can be 
used to desalt a sample as well as separating molecules of different molecular weights. 
The Superdex 200 10/300 GL column can be used for SEC and has a separation range 
for molecules with molecular weights between 10-600 kDa. This was used both to 
remove contaminants and desalt the sample. 
Fraction C13 A4 C14 A4 C14 A5 C15 A3 C15 A4 D1 A3 
Concentration (nM) 96 202 251 133 420 416 
Yield (μg) 13 27 34 18 57 56 
 
Fraction D2 A3 D2 A4 D3 A2 D3 A3 D4 A2 D4 A3 
Concentration (nM) 476 592 160 278 43 111 




Figure 3.15-Heparin binding purification of EGFPsAPPα Δ608-612 
(A): Heparin binding chromatogram of EGFPsAPPα Δ608-612 FPLC. The red bar indicates fractions 
tested for the presence and purity of EGFPsAPPα Δ602-612. The blue line represents the A280. The brown 
line represents NaCl conductance. (B): Colloidal Coomassie stained SDS-PAGE gel of heparin purified 
EGFPsAPPα Δ602-612 fractions. Marker; Broad range protein marker. sAPPα; Purified sAPPα positive 
control. C6-D1; Heparin affinity purified EGFPsAPPα Δ608-612 fractions. 
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EGFPsAPPα Δ608-612 containing fractions C7-C10 from the heparin binding FPLC 
chromatogram were pooled together and 6 runs of SEC were performed in order to 
separate contaminating protein from EGFPΔ608-612. The chromatogram displayed 
multiple peaks, suggesting separation of proteins with differing molecular weights 
(Figure 3.16A).  
Figure 3.16 Size exclusion FPLC of heparin purified EGFPsAPPα Δ608-612 
Heparin purified fractions EGFPsAPPα Δ608-612 C7-C10 (1 mL/fraction) were pooled together and 
subjected to SEC. Pooled EGFPsAPPα Δ608-612 (800μL/run) was injected through a 1mL loop into the 
FPLC system. (A): Run 3 SEC chromatogram of heparin purified EGFPsAPPα Δ608-612. The arrow 
indicates A280 peak containing EGFPsAPPα Δ608-612. The red bar represents fractions tested for the 
presence and purity of EGFPsAPPα Δ608-612. The blue line represents the A280. The brown line 
represents NaCl conductance. (B): Colloidal Coomassie stained SDS-PAGE gels of EGFPsAPPα Δ608-
612 SEC runs 2-6. Run 1 fractions contained no EGFPsAPPα Δ608-612 and was omitted. Marker; Broad 
range protein marker. sAPPα; Purified sAPPα positive control. Run 2 A12 – Run 6 A10; SEC purified 
EGFPsAPPα Δ608-612 fractions. 
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Colloidal Coomassie stained gel analysis determined that the second, smaller peak in 
the chromatogram eluted fractions containing EGFPsAPPα Δ608-612 (Figure 3.16B). 
SEC also successfully removed contaminating protein that was in these samples. 
Purified fractions of EGFPsAPPα Δ608-612 were then compared to sAPPα standards 
of known concentrations (Figure 3.17). EGFPsAPPα Δ608-612 yields were quantified 
via densitometry and are presented in Table 3.4. 
Figure 3.17 – Western quantification of EGFPsAPPα Δ608-612 
Western blot of known sAPPα standards against SEC purified EGFPsAPPα Δ608-612. Primary antibody 
= anti-N-terminal APP. Secondary antibody = anti-rabbit HRP. Marker; Broad range protein marker. 
sAPPα standards (nM); purified sAPPα of indicated concentrations. Run 1 A14 – Run 6 A9; Size 
exclusion fractions from run 1 through to run 6. 
EGFPsAPPα Δ608-612 gave much lower yields in comparison to EGFPsAPPα and 
EGFPsAPPβ. This was likely to due to the loaded sample being of low concentration. 





Table 3.4 Purified EGFPsAPPα Δ608-612 yields 
 Run 2 Run 3 Run 4 
EGFPsAPPα 
Δ608-612 Fractions 
A12 A13 A14 A15 A8 A9 A10 A11 A12 A13 A7 A8 
Concentration (nM) 0 196 172 18 0 3.4 285 248 115 75 49.0 108 
Yield (μg)  13 12 1.2 0 0.2 19 17 7.9 5.1 3.3 7.4 
 
 Run 4  Run 5  Run 6 
EGFPsAPPα  
Δ608-612 Fractions 
A9 A10 A11 A3 A4 A5 A6 A7 A6 A7 A8 A9 
Concentration (nM) 259 227 98 0 13 192 452 312 2.3 166 234 67  




3.4.2 EGFPsAPPα K612A purification and yield quantification 
In comparison to EGFPsAPPα Δ608-612, heparin binding purification of EGFPsAPPα 
K612A produced a smaller A280 peak in the suspected elution region (Figure 3.18A). 
However, EGFPsAPPα K612A was still inferred to be present in fractions C3-C8 at 
detectable quantities and these were examined (Figure 3.18B). 
Figure 3.18 - Heparin binding purification of EGFPsAPPα variant K612A  
(A): Heparin binding FPLC chromatogram of EGFPsAPPα K612A. The black arrow indicated suspected 
EGFPsAPPα K612A elution peak. The red bar indicated fractions analysed for the presence and purity 
of EGFPsAPP αK612A. The blue line represents the A280. The brown line represents NaCl 
conductance. 
(B): Colloidal Coomassie analysis of fractions that may contain EGFPsAPPα K612A. The black arrow 
indicates the region of EGFPsAPPα K612A. Marker; Broad range protein marker. sAPPα; purified 
sAPPα positive control. B11 – D8; Heparin purified EGFPsAPPα K612A fractions. 
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Fractions C5 & C6 contained EGFPsAPPα K612A and little contaminating protein. 
Therefore, these fractions underwent a final desalting step to complete the purification 
process (data not shown). Final desalted fractions were analysed for purity and 
quantified against sAPPα standards of known concentrations (Figure 3.19). The 
concentrations of EGFPsAPPα K612A was then calculated and are presented in Table 
3.5  
Figure 3.19 – EGFPsAPPα K612A purity and yield determination 
(A): Colloidal Coomassie stain of final desalt purified EGFPsAPPα K612A. (B): Western blot of final 
desalt purified EGFPsAPPα K612A against known sAPPα standards. Primary antibody = anti-N-
terminal APP. Secondary antibody = anti-rabbit HRP. Marker; Broad range protein marker. sAPPα 
standards; Purified sAPPα samples of known concentrations. C5A3-C6A3; Final desalted EGFPsAPPα 
K612A fractions. 
Table 3.5 – Purified EGFPsAPPα K612A yields  
EGFPsAPPα 
K612A 
C5A3 C5A4 C6A2 C6A3 
Concentration 
(nM) 
100 16 64 73 
Yield (μg) 14 2.2 9.0 10 
Further purification was attempted with fractions C3, C4, C7 and C8 due to the 
prominent amounts of contaminating protein. EGFPsAPPα K612A was however 




3.4.3 EGFPsAPPα Δ602-612 & RER328AAA purification and yield quantification 
As for the other EGFPsAPP proteins, the deletion and the substitution in EGFPsAPPα 
Δ602-612 and EGFPsAPPα RER328AAA respectively were not expected to affect 
heparin binding capacity. Therefore the same strategy was used to purify these 
proteins. 
The A280 profiles in both the EGFPsAPPα Δ602-612 and RER328AAA heparin binding 
chromatograms displayed no clear peak characteristic of sAPPα elution (Figure 3.20A 
& B) This absence was further supported by the lack of EGFPsAPPα bands in colloidal 
Coomassie stained SDS-PAGE gels (Figure 3.20C & D). Furthermore, the overall A280 
in EGFPsAPPα Δ602-612 heparin binding purification was high, corresponding with 
an increased contaminant protein throughout the affinity purification procedure. 
Figure 3.20 – Heparin binding FPLC of EGFPsAPPα Δ602-612 & RER328AAA 
(A & B): Heparin binding FPLC chromatograms of EGFPsAPPα Δ602-612 & RER328AAA respectively. 
The blue line represents the A280. The brown line represents NaCl conductance. (C & D): Colloidal 
Coomassie stained gels of heparin purified EGFPsAPPα Δ602-612 & RER328AAA respectively. The red 
bars indicate fractions tested for the presence of target protein. Marker; Broad range protein marker. 
sAPPα; purified sAPPα positive control. C10-D4; EGFPsAPPα Δ602-612 heparin affinity purified 
fractions. B9-C3; EGFPsAPPα RER329AAA heparin affinity purified fractions. 
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As no EGFPsAPPα Δ602-612 or RER328AAA protein was detected, the HEK293T 
stable cell lines in which they were expressed were analysed for their fluorescence. 
Fluorescence microscopy analysis showed that the amount of expressing cells made 
up now only a small proportion of the entire cell population (Figure 3.21), a surprising 
observation as original fluorescence analysis displayed higher proportions of 
expressing cells (Figure 3.5). 
Figure 3.21 – Low expression of HEK293T EGFPsAPPα Δ602-612 & RER328AAA 
stable cell lines 
Stable cell lines were seeded at 5 x 105 cells/mL and were visualised 24 h later. Cells were viewed under 




To enrich for the expressing EGFPsAPPα Δ602-612 & RER328AAA cells, fluorescing 
cells were separated from non-fluorescing cells by fluorescence activated cell sorting 
(FACS). GFP fluorescence detection was set so that non-transfected or non-expressing 
HEK293T cells were exempt from positive selection. FACS analysis confirmed that 
only 0.82% of EGFPsAPPα Δ602-612 and 2.00% of EGFPsAPPα RER328AAA cultures 
were exhibiting fluorescence and therefore expressing the EGFPsAPPα variant 
proteins (Figure 3.22). The positive cells were collected and re-seeded into new flasks 
for media collection and subsequent protein purification. 
Figure 3.22 – Enrichment of EGFPsAPPα Δ602-612 and RER328AAA cultures 
through fluorescent activated cell sorting (FACS). 
The positive selection threshold was set for any cell fluorescing more than non-transfected HEK293T 
negative control cell suspensions. (A): FACS sorting of transfected HEK293T EGFPsAPPα Δ602-612. 
(B): FACS sorting of transfected HEK293T EGFPsAPPα RER328AAA. SSC-A – the area of side scattered 





Fluorescence microscopy analysis of post-FACS sorted cells confirmed an enrichment 
of expressing EGFPsAPPα Δ602-612 and RER328AAA cultures (Figure 3.23). These 
findings were further supported by an increase in target protein concentrations 
(Figure 3.24). 
Figure 3.23 – Post FACS sorted HEK293T EGFPsAPPα Δ602-612 & EGFPsAPPα 
RER328AAA stable cell lines. 
HEK293T EGFPsAPPα Δ602-612 and EGFPsAPPα RER328AAA cultures were viewed under bright 
field (left) and for GFP fluorescence (right). 
Media from culturing the EGFPsAPPα Δ602-612 and EGFPsAPPα RER328AAA cells 
was collected and subjected to the standard sAPPα purification protocol. Post-FACS 
heparin binding purification showed a much larger sAPPα peak for both variants 
(Figure 3.24). The presence of EGFPsAPPα variants was further confirmed by colloidal 
Coomassie gel staining. Fractions of interest also contained a light background of 




Figure 3.24 – Heparin affinity purification of post-FACS EGFPsAPPα Δ602-612 and 
RER328AAA 
(A&B): Heparin binding FPLC chromatogram of post-FACS EGFPsAPPα Δ602-612 and EGFPsAPPα 
RER328AAA respectively. The red bar indicates fractions of interest analysed for the presence of target 
protein. The black arrow represents the suspected target protein elution A280 peak. The blue line 
represents the A280. The brown line represents NaCl conductance. (C&D): Colloidal Coomassie of 
fractions of interest from heparin purified post-FACS EGFPsAPPα Δ602-612 and EGFPsAPPα 
RER328AAA respectively. Marker; Broad range protein marker. B14-C11; Post-FACS heparin affinity 
purified EGFPsAPPα Δ602-612. B7-C4; Post-FACS heparin affinity purified EGFPsAPPα RER328AAA. 
  


















80.0 90.0 100.0 110.0 ml
A4 A5 A6 A7 A8 A9 A10A11A12A13A14A15 B1 B2 B3 B4 B5 B6 B7 B8 B9 B10B11B12B13B14B15 C1 C2 C3 C4 C5 C6 C7 C8 C9 C10C11 C13 Waste


















85.0 90.0 95.0 100.0 105.0 110.0 115.0 120.0 ml





The heparin purified EGFPsAPPα Δ602-612 and EGFPsAPPα RER328AAA fractions 
were subjected to a final desalting column. The salt was successfully removed and the 
fractions were found to be of relatively high purity (Figure 3.25), although 
EGFPsAPPα RER328AAA containing fractions had an additional 66 kDa protein. 
Fractions with significant amounts of target protein, C5 for Δ602-612 and B13 for 
RER328AAA, were further purified by SEC in order to determine whether loss of 
protein was due to low concentrations of loaded material (Figure 3.26). 
Figure 3.25 – Final desalt of EGFPsAPPα Δ602-612 and RER328AAA 
(A): 5th run final desalt FPLC chromatogram of post-FACS EGFPsAPPα Δ602-612. (B): 3rd run final 
desalt FPLC chromatogram of post-FACS EGFPsAPPα RER328AAA. (C&D):  Colloidal Coomassie gel 
staining (top panel) and Western immunoanalysis (bottom panel) of fractions of interest eluted from 
final desalt FPLC of EGFPsAPPα Δ602-612 and EGFPsAPPα RER328AAA respectively. Primary 
antibody = anti-N-terminal APP. Secondary antibody = anti-rabbit HRP. Marker; Broad range protein 
marker. C1A2-C8A3; Post-FACS final desalt purified EGFPsAPPα Δ602-612. B10A2-C1A3; Post-FACS 
final desalt purified EGFPsAPPα RER328AAA. 
 Manual run 9:10_UV1_280nm  Manual run 9:10_Cond  Manual run 9:10_Fractions  Manual run 9:10_Inject












26.0 28.0 30.0 32.0 34.0 ml
A1 A2 A3 Waste
 Manual run 9:10_UV1_280nm  Manual run 9:10_Cond  Manual run 9:10_Fractions  Manual run 9:10_Inject
















126.0 128.0 130.0 132.0 134.0 ml





EGFPsAPPα Δ602-612 fractions still contained contaminating proteins following SEC 
(Figure 3.25). Some of these proteins were detected in both the Commassie stained gel 
and the Western blot, which suggests that EGFPsAPPα Δ602-612 has been degrading 
into smaller protein fragments. The 66 kDa protein detected by final desalt of 
EGFPsAPPα RER328AAA (Figure 3.25 D) was also detected in SEC of EGFPsAPPα 
Δ602-612 (Figure 3.26 C). SEC of EGFPsAPPα RER328AAA was successful in 
removing all contaminating protein (Figure 3.26D) 
The purified EGFPsAPPα Δ602-612 & EGFPsAPPα RER328AAA were then quantified 
against known sAPPα standards (Figure 3.27) EGFPsAPPα Δ602-612 & EGFPsAPPα 





Figure 3.26 – Size exclusion chromatography of EGFPsAPPα Δ602-612 & 
EGFPsAPPα RER328AAA 
One concentrated fraction (1mL) of heparin affinity purified EGFPsAPPα Δ602-612 and RER328AAA 
was subjected to SEC to determine whether using concentrated loads increases the likelihood of target 
protein detection. (A): A chromatogram of the 2nd SEC run of EGFPSAPPα Δ602-612. (B): A 
chromatogram of the 1st SEC run of EGFPsAPPα RER328AAA. (C): Colloidal Coomassie gel staining 
(top panel) and Western immunoanalysis (bottom panel) of size exclusion purified EGFPsAPPα Δ602-
612 fractions of interest. (D): Colloidal Coomassie gel staining (top panel) and Western immunoanalysis 
(bottom panel) of size exclusion purified EGFPsAPPα RER328AAA fractions of interest. Primary 
antibody = anti-N-terminal APP. Secondary antibody = anti-rabbit HRP. In both of the FPLC 
chromatograms the blue represents A280 measurements and the brown line represents the salt 
conductance. Marker; Broad range protein marker. C1A2-C8A3; Post-FACS final desalt purified 
EGFPsAPPα Δ602-612. B10A2-C1A3; Post-FACS final desalt purified EGFPsAPPα RER328AAA. 
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Figure 3.27 - Quantification of EGFPsAPPα Δ602-612 & EGFPsAPPα RER328AAA 
(A): Western immunoanalysis of final desalt purified EGFPsAPPα Δ602-612 compared to sAPPα 
standards of known concentrations. (B): Western immunoanalysis of final desalt purified EGFPsAPPα 
RER328AAA compared to sAPPα standards of known concentrations. (C): Western immunoanalysis 
of size exclusion purified EGFPsAPPα Δ602-612 and EGFPsAPPα RER328AAA. Primary antibody = 
anti-N-terminal APP. Secondary antibody = anti-rabbit HRP. Marker; Broad range protein marker. 









Fraction C1 A2 C1 A3 C2 A2 C2 A3 C3 A3 C4 A2 C4 A3 
Concentration 
(nM) 
178 89 141 46 80 447 267 
Yields (μg) 24 12 19 6.3 10 61 36 
Fraction C6 A2 C6 A3 C7 A2 C7 A3 C8 A2 C8 A3 
Concentration 
(nM) 
268 142 180 366 152 244 





Run # Run 1 Run 2 
Fraction A4 A4 A5 A6 
Concentration 
(nM) 
160 136 535 149 









Fraction B10 A2 B10 A3 B11 A2 B11 A3 B12 A3 B14 A2 B14 A3 
Concentration 
(nM) 
161 57 142 111 132 324 206 
Yields (μg) 22 7.8 19 15 18 44 28 
Fraction B15 A2 B15 A3 C1 A2 C1 A3 
Concentration 
(nM) 
205 112 91 229 





Run # Run 1 
Fraction A3 A4 A5 
Concentration 
(nM) 
60 224 485 




3.5 Chapter 3 conclusion 
This chapter demonstrates the production and purification of EGFPsAPPα, 
EGFPsAPPβ and EGFPsAPPα variants Δ602-612, Δ608-612, K612A and RER328AAA. 
As has been previously shown by the Tate lab, native sAPPα can be purified by a one 
step heparin binding affinity FPLC protocol, flanked by two desalting steps. Attaching 
the 26 kDa GFP molecule to the N-terminus of sAPPα did not affect the purification 
outcome for the fusion proteins. This suggests that the heparin binding capability of 
EGFPsAPPα (and other variants) has not been interupted. 
Contaminating protein was found in purified fractions of EGFPsAPPα Δ602-612, 
EGFPsAPPα K612A and EGFPsAPPα RER328AAA. Fractions with a high abundance 
of target protein (EGFPsAPPα Δ602-612 and EGFPsAPPα RER328AAA) had 
contaminating protein successfully separated via a second purification strategy using 
SEC. However, in the case of EGFPsAPPα K612A, SEC seemed to have lost all target 
protein. This is thought to be because there was a low initial concentration of 
EGFPsAPPα K612A. Therefore caution should be taken when using this technique for 
purifying target protein at low concentrations. 
Lastly, this chapter demonstrates that fluorescence activated cell sorting (FACS) can 
enrich cell cultures that have lost expression or have a low apparent transfection rate. 
EGFPsAPPα Δ602-612 and EGFPsAPPα RER328AAA had an expression rate of 0.8% 
and 2.0% respectively. Following FACS, both cultures had a much higher proportion 
of cells expressing the respective EGFPsAPPα variant (as determined by the 
proportion of fluorescent cells to non-fluorescent cells). This enrichment of transfected 
cultures were further supported by the increased concentration of target protein 






How does EGFPsAPPα initiate it’s signalling? 
4.1 Context for use of purified EGFPsAPP variants 
In order to determine how secreted amyloid precursor protein alpha (sAPPα) initiates 
its signalling mechanisms, sAPPα and variants, each with N-terminally conjugated 
enhanced green fluorescent proein (EGFP), were prepared and purified as discussed 
in Chapter 3. The rationale for the fusion proteins was to determine whether 
EGFPsAPPα (and the previously described variants) bound to the external cell 
membrane and initiated the known cascade of functions, or whether it was 
immediately internalised to initiate signalling. If events occurred at the plasma 
membrane (PM) then it was hoped it would be detectable by fluorescence microscopy 
or alternative methods that detect fluorescence. 
Confirming that EGFPsAPPα functioned like sAPPα was a crucial first step towards 
the assessment of the previously purified EGFPsAPPα variants. All variants apart 
from EGFPsAPPα were unable to be functionally validated individually due to time 
constraints, but provide a valuable resource for future experiments assessing the 
neuroprotective properties of sAPPα. The neuroprotective regions within sAPPα, 
RER328 and the final C-terminal 16 amino acids, may themselves be useful as 
Alzheimer’s disease (AD) therapies due to their small size. 
4.2 Assessment of the neuroprotective properties of EGFPsAPPα 
The previous chapter showed that adding the 26 kDa EGFP protein to the N-terminus 
of sAPPα did not interfere with the heparin binding capability. The first functional 
property assessed was a determination of whether EGFPsAPPα preserved sAPPα’s 
neuroprotective properties. Previous studies have demonstrated that sAPPα (1 nM) is 




can therefore be used as a positive control when validating EGFPsAPPα’s 
neuroprotective effects. 
SH-SY5Y cells were seeded in 96 well plates (Section 2.3.8) and pre-incubated with 
TAPI-1 (Section 2.3.15) for 24 h to block endogenous sAPPα production. These cells 
were used in the MTT cell viability assay (Section 2.3.16). EGFPsAPPα was applied 
exogenously to analyse the neuroprotective capacity of the protein. Surprisingly, all 
attempts failed to detect a decrease in cell viability in glucose deprived SH-SY5Y cells 
as analysed in the MTT assay (Figure 4.1A). 
Hamid et al. (2004) previously found that the MTT assay is less sensitive than the 
resazurin assay at detecting the effects of a range of drugs on cells. The MTT assay did 
not detect low glucose mediated cellular stress, and this may be a true reflection of the 
physiological state of the cells. Therefore, the more sensitive resazurin assay was tried 
as an alternative. 
A resazurin assay (Section 2.3.17) was conducted using the same variable parameters 
as the previous MTT assay (Figure 4.1B). As with the first assay, there was no 
significant difference found between any of the conditions. With no significant 
difference identified when glucose was omitted from the culture media, it was 
concluded that glucose deprivation itself was not sufficient to create a noticeable insult 
to these particular SH-SY5Y cells. 
During sAPPα purification HEK293T cells were exposed to serum free conditions. It 
was noticed HEK293T cells left too long in serum free conditions shortened their 
cellular processes and eventually died. It was thought that SY-SY5Y cells deprived of 
both glucose and serum might create an insult sufficient enough to be detected by the 
resazurin assay. The media was supplemented with a low level of serum (1% fetal calf 
serum (FCS)), as a complete lack of serum has been shown to cause apoptosis in SH-





Figure 4.1 – Viability of SH-SY5Y cells when deprived of glucose 
SH-SY5Y cells were seeded into a 96 well plate at 5 x 104 cells/well. Once reaching optimal confluency 
(80%) cells were pre-incubated with TAPI-1 (50 μM) for 24 h and throughout the duration glucose 
deprivation. SH-SY5Y cells were pre-incubated with sAPPα (1 nM and 10 nM) and EGFPsAPPα (1 nM 
and 10 nM) 2 h prior to and during 8 h of glucose deprivation. SH-SY5Y cell viability was measured by 
(A): a MTT assay or (B): a resazurin assay. MTT was added 6 h after glucose deprivation while resazurin 
was added 5 h after glucose deprivation. Positive control – SH-SY5Y cells supplemented with glucose. 
Negative control – SH-SY5Y deprived and glucose and treated with 1 x PBS (vehicle). All other 
treatments are as indicated. n = 10. Error bars = SD. *p < 0.05 (One-way ANOVA, Dunnett’s multiple 
comparison test). Outliers removed with a ROUT (Q = 10.00%) test. 
The combinatorial effect of glucose withdrawal and serum deprivation elicited a 
significant loss of viability in SH-SY5Y cells in comparison to cells grown in media 
with glucose (Figure 4.2A). Nevertheless, 1 nM and 10 nM concentrations of sAPPα 
or EGFPsAPPα were unable to rescue these glucose and serum deprived cells.  
SH-SY5Y cells used for these experiments were between passage 13-16. Differentiation 
of SH-SY5Y cells may be controlled by regulatory mechanisms that are lost at higher 
passage number, thereby disinhibiting spontaneous differentiation (Monaghan et al., 
2008). It was therefore decided to use cells from a lower passage number. Furthermore, 
vacuum aspiration of media was shown to remove adherent cells, thereby increasing 





Needle aspiration, a more delicate procedure than vacuum aspiration, reduced the 
variation in SH-SY5Y viability of lower passage cells (Figure 4.2B). Cells deprived of 
glucose were significantly less viable than cells that were grown in glucose. However, 
as seen previously, sAPPα and EGFPsAPPα at all tested concentrations were unable 
to rescue cells significantly from glucose deprivation. This suggests that the insult 
evoked on low passage SH-SY5Y cells by glucose deprivation may be too extreme to 
be rescued by sAPPα and EGFPsAPPα. Media aspiration from here on in was 
performed with a syringe and needle. 
Figure 4.2 – Glucose deprivation and 1% FCS supplementation causes loss in SH-
SY5Y viability 
SH-SY5Y cells were seeded into a 96 well plate at 5 x 104 cells/well. Once reaching optimal confluency 
(80%) cells were pre-incubated with TAPI-1 (50 μM) for 24 h and throughout the duration glucose 
deprivation. SH-SY5Y were pre-incubated with sAPPα (1 nM and 10 nM) and EGFPsAPPα (1 nM and 
10 nM) 2 h prior to and during glucose deprivation. SH-SY5Y cell viability was assessed by cell 
metabolism of resazurin following 5 h of glucose deprivation. Metabolism of resazurin was allowed to 
occur for 3 h. (A): P 15 SH-SY5Y cells deprived of glucose and supplemented with 1% FCS. (B): P5 cells 
deprived of glucose and supplemented with 1% FCS. Cells had media aspirated with a syringe and 
needle instead of vacuum aspiration.  
Positive control – SH-SY5Y cells supplemented with glucose. Negative control – SH-SY5Y deprived and 
glucose and treated with 1 x PBS (vehicle). All other treatments are as indicated. n = 10. Error bars = SD. 
*p < 0.05, ****p < 0.0001 (One-way ANOVA, Dunnett’s multiple comparison test). Outliers were 





By decreasing the amount of time that SH-SY5Y cells are exposed to glucose 
deprivation or by increasing the percentage of FCS in cell media, it could be possible 
to increase the viability of deprived cells while still creating a large enough insult in 
order to detect a difference in viability between glucose conditions. 
Decreasing the glucose deprivation time from 8 h to 4 h resulted in fully viable SH-
SY5Y cells (data not shown). It was hypothesised that a 6 h glucose deprivation may 
be the conditions that best display the neuroprotective effects of sAPPα and 
EGFPsAPPα (Figure 4.3). A wider range of sAPPα concentrations were used in order 
to see if a neuroprotective effect was seen at higher doses. 
Figure 4.3 – sAPPα displays a dose dependent neuroprotective trend following 6 h 
of glucose deprivation. 
Passage 6 SH-SY5Y cells were seeded into a 96 well plate at 5 x 104 cells/well. Once reaching optimal 
confluency (80%) cells were pre-incubated with TAPI-1 (50 μM) for 24 h and throughout the duration 
of glucose deprivation. SH-SY5Y cells were pre-incubated with sAPPα (1 nM, 10 nM, 20 nM and 50 nM) 
2 h prior to and during glucose deprivation. SH-SY5Y cell viability was assessed by cell metabolism of 
resazurin following 3 h of glucose deprivation. Metabolism of resazurin was allowed to occur for 3 h. 
Positive control – SH-SY5Y cells supplemented with glucose. Negative control – SH-SY5Y deprived and 
glucose and treated with 1 x PBS (vehicle). n = 10. Error bars = SD. *p < 0.05, **p < 0.01 (One-way 




Conditions demonstrated a significant difference in SH-SY5Y cell viability between 
glucose positive and glucose null conditions. Although non-significant, a possible 
neuroprotective trend is apparent with increasing sAPPα concentration. Again, it is 
likely that the insult inflicted on SH-SY5Y cells was too severe to be recovered from 
by sAPPα application. Therefore, it was hoped that in using the aforementioned 
conditions (6 h glucose deprivation, needle aspiration and low SH-SY5Y passage) and 
increasing the FCS supplementation to 2% may produce an insult severe enough to 
generate a significant viability loss between glucose conditions, but mild enough be 
recovered from by sAPPα or EGFPsAPPα application. 
Increasing the amount of FCS in media from 1% to 2% resulted in a lower loss of 
viability in deprived SH-SY5Y cells, however a highly significant difference was still 
seen between glucose containing and glucose deprived conditions (Figure 4.4). 
EGFPsAPPα (10nM) now showed a significant 17.8% increase in SH-SY5Y cell 
viability (p = 0.0225), suggesting that EGFPsAPPα still contains neuroprotective 
properties despite the N-terminally conjugating GFP. However as sAPPα was unable 
to exhibit neuroprotection a new method of 
functional validation was required. 
Figure 4.4 – EGFPsAPPα exhibits neuroprotection 
in low passage SH-SY5Y cells deprived of glucose 
and supplemented with 2% FCS 
Passage 6 SH-SY5Y cells were seeded into a 96 well plate at 5 
x 104 cells/well. Once reaching optimal confluency (80%) cells were pre-incubated with TAPI-1 (50 μM) 
for 24 h and throughout the duration glucose deprivation. SH-SY5Y were pre-incubated with sAPPα (1 
nM and 10 nM) and EGFPsAPPα (1 nM and 10 nM) 2 h prior to and during glucose withdrawal and 
serum deprivation (2%). SH-SY5Y cell viability was assessed by cell metabolism of resazurin following 
3 h of trophic deprivation. Metabolism of resazurin was allowed to occur for 3 h. Positive control – SH-
SY5Y cells supplemented with glucose. Negative control – SH-SY5Y deprived and glucose and treated 
with 1 x PBS (vehicle). n = 5. Error bars = SD. *p < 0.05, ****p < 0.0001 (One-way ANOVA, Dunnett’s 




4.3 Electrophysiological validation of EGFPsAPPα 
EGFPsAPPα demonstrated suggestive neuroprotection from glucose and FCS 
deprivation in SH-SY5Y cells, as displayed by the resazurin assay. However, these 
viability assays were unable to develop reproducible convincing data to validate the 
function of EGFPsAPPα, so a new approach was required. Long term potentiation 
(LTP) is currently the best available model of mammalian memory. Previous research 
has shown that sAPPα can enhance long-term potentiation (LTP) in Sprague-Dawley 
rat hippocampal slices (Jodi Morrissey, unpublished findings). Therefore, in using this 
method it was possible to validate whether EGFPsAPPα is still functionally active. 
A baseline stimulation was given until no fluctuations in field excitatory postsynaptic 
potentials (fESPSs) were observed. EGFPsAPPα was bath-applied for 25 min before 
and 5 min after tetanus stimulation. Non-saturated LTP was induced by applying a 
“half” theta burst stimulus at baseline stimulus intensity. fESPSs were measured and 
resulting data from the vehicle, sAPPα and EGFPsAPPα washed slices were 
compared. Upon tetanus stimulation, sAPPα and EGFPsAPPα enhanced an increase 
in fESPSs in comparison to the vehicle control (Figure 4.5). 
Figure 4.5 - sAPPα and EGFPsAPPα enhance LTP rat in hippocampal slices 
Facilitation of LTP by sAPPα and EGFPsAPPα. Injection of sAPPα (1 nM; blue) or EGFPsAPPα (1 nM; 
green) produced facilitation of LTP compared to a control treatment of PBS (red). n = 3 per condition, 




This suggests more convincingly that EGFPsAPPα is functioning qualitatively and 
quantitatively like sAPPα to enhance neuroplasticity, implying that the EGFP on 
sAPPα’s N-terminus does not inactivate sAPPα in inducing memory functions. 
4.4 Fluorescence analysis of EGFPsAPPα 
As the functional validation for EGFPsAPPα was finally confirmed via induction of 
LTP, it was now possible to investigate the initiation of EGFPsAPPα signalling via cell 
surface analysis. 
4.4.1 - Fluorescence microscopy of EGFPsAPPα applied cell cultures 
sAPPα can cause changes in gene expression after 15 min incubation with 
hippocampal slices, therefore it was thought that the sAPPα’s initiation of signalling 
is likely to occur in a small time window. If sAPPα binding is only transient, then it 
would be best to analyse EGFPsAPPα binding at short intervals from 0-15 min after 
addition. EGFPsAPPα (20 nM) was applied and fluorescence tested at various 
incubation times ranging from 30 s to 10 min, but again no fluorescence was observed 
(Appendix III). Increasing the concentration of EGFPsAPPα to well over its working 
dose in addition to application of heparin (5 U/mL) still resulted in no detectable 
fluorescence within SH-SY5Y cells (Appendix III). 
As all cells within the human body express an isomer of APP, non-neuronal cells 
should have the ability to bind sAPPα and therefore possibly EGFPsAPPα. 
EGFPsAPPα (20 nM) was applied to HEK293T cells but again no fluorescent signal 
was observed from all time points ranging between 1 and 10 minutes (Appendix III). 
TAPI-1, a potent inhibitor of endogenous sAPPα synthesis, was not used initially in 
these fluorescence microscopy experiments, so that endogenous sAPPα production 
would not have been inhibited. If the number of putative sAPPα receptors is sparse 
then detection of EGFPsAPPα fluorescence may be difficult under competition from 




to inhibit endogenous sAPPα production had no effect on the detection of 
EGFPsAPPα signal (Appendix III). 
In order to detect low levels of EGFPsAPPα cell surface binding, exposure levels of 
microscopic images were enhanced so that negative controls displayed low levels of 
fluorescent signal, thereby enhancing any fluorescent signal in cells incubated with 
EGFPsAPPα. Enhanced exposure of EGFPsAPPα applied to SH-SY5Y cultures for 0-
10 min displayed a fluorescent signal from 1 to 10 min (Figure 4.6). Significantly longer 
times of incubation showed less distinct binding (Appendix III). Although the results 
obtained from these images are only qualitative, they indicate short incubation times 
with EGFPsAPPα are appropriate in order to detect whether cell surface binding or 
internalisation occurs. 
It was concluded that expression of cell surface sAPPα receptors may be low and 
detecting EGFPsAPPα cell surface binding was challenging, therefore a new method 






Figure 4.6 – EGFPsAPPα binding to SH-SY5Y cell surfaces is implied with enhanced exposure 
The binding of EGFPsAPPα to SH-SY5Y cells was detected at 1 min and did not fluctuate greatly. This indicates that EGFPsAPPα binding to SH-SY5Y cells was 
saturated at 1 min (A): Cells were seeded at 5 x 105 cells/mL in a 24 well plate and were grown for 24 h. EGFPsAPPα (20 nM) was then applied to SH-SY5Y 
cultures for the indicated times. Cells were fixed in 4% PFA before being visualised by bright field microscopy (top panel), for EGFP fluorescence (middle 
panel) and for Hoescht 33342 DNA staining (bottom panel).
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4.4.2 – Immunocytochemistry of EGFPsAPPα applied SH-SY5Y cultures 
Immunocytochemistry is commonly used to visualise the location of a specific protein 
within a cell. Here we aimed to amplify the signal of EGFPsAPPα by targeting the 
fusion protein with primary anti-EGFP antibodies. Multiple secondary antibodies can 
bind to a primary antibody and therefore allows amplification of any EGFP signal 
present within or on a cell (Figure 4.7) 
Figure 4.7 – Schematic diagram comparing EGFPsAPPα fluorescence vs 
EGFPsAPPα immunocytochemistry. 
In comparison to conventional fluorescence microscopy, immunocytochemistry can enhance the 
amount of fluorophores binding to a target antigen. This enhances the likelihood that a target molecule 
will be visualised through techniques that measure fluorescence. 
In order to quantify the amount of EGFPsAPPα that binds to SH-SY5Y cells, the 
sensitivity of anti-EGFP antibodies was determined. The suppliers of these 
commercially available antibodies claimed to detect down to 5 ng, however this study 
was able to detect down to 1 ng of EGFP (Figure 4.8). 
Figure 4.8 – Commercially available anti-GFP antibody detects down to 1 ng. 
Blot was probed for EGFPsAPPα of known amounts to determine the detection sensitivity of 
commercial anti-GFP antibody. Primary antibody = Anti-GFP. Secondary antibody = IRDye® 680RD 
anti-rabbit. 
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EGFPsAPPα produced by the stably expressing HEK293T cell line was able to be 
detected through immunocytochemistry (Figure 4.9). The fluorescence from the 
Alexa-conjugated secondary antibody was noticeably stronger than that of the EGFP 
fluorescence. Despite increasing the detection sensitivity, immunocytochemistry was 
still unable to detect applied EGFPsAPPα binding to SH-SY5Y cells. In conclusion, 
without enhanced exposure, both general GFP fluorescence and 
immunohistochemistry were unable to detect EGFPsAPPα binding/internalisation, 
likely being a detection issue regardless of attempts in increasing sensitivity. 
4.4.3 – Flow cytometry detection of EGFPsAPPα cell surface binding. 
Flow cytometry was previously used in this study to separate EGFPsAPPα transfected 
cells from non-transfected cells. It was hypothesised that in using the same technology 
it might be possible to detect EGFPsAPPα binding to SH-SY5Y membranes. 
Furthermore, it was proposed that if sAPPα bound to a target receptor via the proteins 
heparin binding domain, then a PBS heparin wash may either compete or aid with the 
binding site to alter the amount of EGFPsAPPα that is bound. 
Flow cytometry only detected a non-significant 0.02% difference in fluorescence 
between cells washed in EGFPsAPPα and cells absent of EGFPsAPPα (Figure 4.10). 
Flow cytometry was therefore also not sensitive enough to detect EGFPsAPPα 
binding. 




Figure 4.9 – Immunocytochemistry to detect EGFPsAPPα cell surface binding 
Cells were seeded at 5 x 105 cells/mL into a 24 well plate 24 h prior to experimentation. EGFPsAPPα was then applied at 20 nM for the indicated times and cells 
were fixed in 4% PFA. Fixed cells were immunostained for GFP using a rabbit polyclonal anti-GFP antibody. Secondary antibody = Anti-rabbit Alexa Fluor®514. 
dsDNA was stained with Hoechst (1:10,000; Life Technologies, Gaithersburg, MD). 
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Figure 4.10 – EGFPsAPPα binding cannot be detected by flow cytometry 
SH-SY5Y cells were incubated in EGFPsAPPα (20 nM) for 10 min and washed with PBS absent of, or 
containing 5 U/mL heparin. Cells were then resuspended in FACS buffer at 2 x 107 cells/mL and 
subjected to flow cytometry analysis. The positive selection threshold was set for any cell fluorescing 
more than SH-SY5Y cells in the absence of EGFPsAPPα. SSC-A – the area of side scattered light. GFP-
A – the area of GFP fluorescence intensity. 
4.4.4 – Total internal reflection fluorescence microscopy (TIRFM) of EGFPsAPPα 
applied cell cultures 
To validate sAPPα’s interaction with other cell surface proteins, single molecule 
detection microscopy can be used. This experimental technology allows for the 
observation of molecular dynamics in live cells. The most popular method is that of 
total internal reflection fluorescence microscopy (TIRFM). A laser beam strikes a 
glass/water/cell interface with a higher incidence angle than a specific critical angle 
and is totally reflected. This generates a very thin electromagnetic field (evanescent 
wave) which excites fluorophores attached to target molecules. The penetration depth 
is usually 50-100 nm axially to the cell, allowing researchers to observe single 
molecules only located in the cell membrane (Kwakowsky et al., 2013). Should 
EGFPsAPPα bind to its putative receptor and become internalised, it should be 
detectable in using this highly sensitive technique. 
Application of EGFPsAPPα showed fluorescent particles entering and exiting the 
scope of the visual field. Single molecule detection of membrane receptor motility has 
previously been described (C. M. Anderson et al., 1992). Single EGFPsAPPα molecules 
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appeared to move in similar patterns (Figure 4.11), implying that EGFPsAPPα binds 
to SH-SY5Y PMs. The original video of EGFPsAPPα TIRFM and overlay of manually 
tracked EGFP molecules can be found in Appendix IV. 
Figure 4.11 – EGFPsAPPα binds to SH-SY5Y membranes during TIRFM 
P10 SH-SY5Y cells were seeded onto glass coverslips at 5 x 105 cells/ml (2 mL/slip) and were grown 
overnight before being subjected to TIRFM. (A):  SH-SY5Y cells under TIRFM. Cells were incubated in 
EGFPsAPPα (20 nM) for 10 min and were washed with PBS. Each frame was taken at 250ms intervals. 
Frames progress firstly from left to right before starting on a new row. The yellow arrows indicate a 
manually tracked EGFP molecule. (B): EGFPsAPPα motility on SH-SY5Y extracellular membranes 
recorded at 50 ms intervals. Scale has been increased 3 fold from original image to allow for easier 
viewing of EGFP traces. Dots represent where traces begin. Trace 1 = Frame 618 – 725 (5.35s). Trace 2 = 
Frame 837 – 873 (1.8s). Trace 3 = Frame 863 – 891 (1.4s). 
A 
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4.6 Chapter 4 conclusion 
The aims of this chapter were to validate whether adding an EGFP to the N-terminus 
of sAPPα functionally perturbed the protein. Furthermore, if EGFPsAPPα was found 
to be functional, we aimed to determine whether the protein bound to neuroblastoma 
PMs and whether it was internalised. 
Previously using the MTT cell viability assay, the Tate lab has demonstrated sAPPα 
neuroprotection from glucose deprivation in SH-SY5Y cells. The same method was 
unable to replicate this and thereby validate EGFPsAPPα functionally as 
neuroprotective against glucose deprivation. The increased sensitivity of the resazurin 
assay was able to suggest significant neuroprotection in EGFPsAPPα (10 nM, Figure 
4.4) treated cells, however results were inconsistent and unconvincing. 
sAPPα enhances LTP in rat hippocampal slices, therefore it was possible to validate 
EGFPsAPPα function through this slice electrophysiology. EGFPsAPPα caused a 
similar incremental increase in ESPSs to sAPPα, thereby validating EGFPsAPPαs 
capability to enhance LTP. 
Unfortunately, EGFPsAPPβ and the EGFPsAPPα variants purified in Chapter 3 were 
unable to be functionally validated due to time and availability of electrophysiology 
rigs. However, functional validation of EGFPsAPPα implies that adding EGFP to 
sAPPβ and other sAPPα variants should not sterically constrain these fusion proteins, 
and therefore these proteins are likely to still be functional. The purified EGFPsAPPβ 
and EGFPsAPPα variants therefore will provide a valuable resource in future 
experimentation. 
Enhanced exposure during standard fluorescence microscopy suggested binding of 
EGFPsAPPα to SH-SY5Y cells. Nevertheless, the more sensitive 
immunocytochemistry and flow cytometry failed to detect binding and/or 
internalisation of EGFPsAPPα. The TIRF microscope has increased sensitivity and can 
record images of single molecules in real time. In using this microscope, EGFPsAPPα 
(20 nM) was observed to bind to the SH-SY5Y cells. This is seen as single EGFP 
fluorophores “zig-zagging” along SH-SY5Y cell surfaces.  
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The loss of EGFP signal following membrane binding could be indicative of sAPPα 
internalization or disassociation of a sAPPα-receptor complex. Blocking of endocytic 
membrane trafficking by reduction in temperature may hint towards whether sAPPα 
signalling is mediated through internalization or due to ligand-membrane receptor 
interactions (Punnonen et al., 1998). 
  





5.1 Purification and quantification of EGFPsAPP variants 
sAPPα initiates many functional outcomes that have been believed to be mediated 
through receptor binding. Numerous putative binding partners have been suggested 
but none have been thoroughly investigated. Here I aimed to investigate the binding 
and interaction of sAPPα to a neuroblastoma cell line utilising the fluorescent 
EGFPsAPPα fusion protein. This was achieved by conjugating EGFP to the N-
terminus of sAPPα and visualising binding through various forms of microscopy and 
other fluorescence-detecting technologies. 
sAPPα has been purified previously by the Tate lab with one-step heparin binding 
FPLC (Ryan et al., 2013, Turner et al., 2007, Taylor et al., 2008). As EGFP is a 26 kDa 
protein, conjugating it to the N-terminus of sAPPα could have severe structural 
ramifications within the heparin binding domains of sAPPα. This would have 
weakened the binding of EGFPsAPPα (and other variants) to heparin, preventing or 
altering the purification profile on a heparin binding column. The first aim of this 
study was to determine whether EGFPsAPP variants could be purified by the same 
protocol used to purify sAPPα. 
5.1.1 sAPPα heparin binding domains are not functionally perturbed by EGFP. 
Cell cultures with high proportions of EGFPsAPP variant expressing cells had media 
collected, concentrated and purified by one-step heparin binding FPLC. As observed 
with sAPPα purification, each variant produced the well characterised heparin 
binding profile with the exception of EGFPsAPPα Δ608-612 and K612A, where low 
target protein concentrations on a background of non-target protein resulted in the 
A280 peak being less defined. Further analysis of fractions with higher protein 
concentration confirmed the presence of EGFPsAPP variants.  
   
98 
 
Generally, there was little difference in the elution positions of sAPPα and EGFPsAPP 
variants, suggesting that conjugating EGFP to sAPPα’s N-terminus does not interfere 
with the proteins’ heparin binding capacity. EGFPsAPP variants eluted at the same 
salt concentrations as sAPPα, implying that all of the multiple heparin binding 
domains within EGFPsAPP variants are functional.  
5.1.2 FACS, an alternative selection tool for transfected cells. 
Transfected HEK293T stable cell lines that expressed EGFPsAPPα variants Δ602-612 
and RER328AAA initially displayed a high stable integration rate as determined by 
the proportion of the cell population that was fluorescing. Following 
cryopreservation, reseeding and growth of cells, the proportion of EGFPsAPP variant 
expressing cells heavily diminished. 
Although non-significant, sAPPα K612A further enhances viability loss when applied 
to glucose deprived SH-SY5Y cells (Mukadam, A., 2009). If expression of either of the 
EGFPsAPP variants were neurotoxic to cells, the expressing cell population would 
begin to reduce in number. Furthermore, small populations of non-transfected cells 
that survived G418 selection can compete better for nutrients and growth against 
transfected cells. Transfected cells could be at a growth disadvantage when competing 
with non-transfected cells as they are expending significant energy in EGFPsAPPα 
production. More likely however, neurotoxic effects of EGFPsAPPα variants would 
inhibit cell growth. 
This study described a developed method by which G418-resistant non-expressing or 
non-transfected cells can be removed from a transfected cell population, thereby 
enriching for expressing cells. As expressing cells produce a fluorescent product, they 
can be isolated using FACS. HEK293T EGFPsAPPα Δ602-612 and RER328AAA 
cultures were subjected to FACS to enrich for the expressing cells (0.8-2.8%) within 
the populations. This low relative expression from the non-enriched culture was 
reflected in the very low abundance of target protein following concentration of media 
and FPLC purification. Following FACS, expressing cells constituted ~80-95% of the 
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total cell population, and EGFPsAPP variants were abundant in the media and readily 
purified 
5.1.3 Limitations and alternative methods to FCS starvation 
Nutrient limitation has been identified as one of the primary causes of cell culture 
viability loss (Al-Rubeai & Singh, 1998; Tey et al., 2000), serum deprivation in 
particular being recognised as a major factor in cell apoptosis (Maestre et al., 2003; 
Risbud et al., 2005). Transfected HEK293T cells were starved of FCS to eliminate the 
proteins within the FCS from the purification process. Some cells likely underwent 
apoptosis and leaked intracellular proteins into the surrounding media in from which 
EGFPsAPP variants are concentrated and purified from. This increase in 
contaminating protein was evident in some SDS PAGE profiles as a low general 
background, though other secreted proteins were likely responsible for most non-
target protein reflected in the A280 readings from heparin binding FPLC profiles. On 
occasion target protein A280 peaks were less defined and consequently fractions 
containing target protein also contained more protein contaminants. 
FCS could be retained in the media, but then more stringent multistep purification 
methods would be required. As sAPPα has multiple metal binding domains, a 2-step 
initial desalt, heparin binding, immobilised metal ion affinity column (IMAC) and 
final desalt might form an alternative purification procedure. However, at each step 
losses of target protein occurs and therefore there are advantages of being able to use 
a one-step protocol. In the best preparations, cell expression of sAPPα variants is high, 
and background contaminants are reduced to near insignificance. 
5.1.4 SEC is not effective with low yield loads 
Size exclusion purification heavily dilutes the sample by 3 fold and therefore the target 
protein, when in low concentration, was not detected. The final desalting column also 
dilutes the sample concentration by no more than two fold, but does not remove 
protein contaminants. For future purifications, where there is an abundance of 
   
100 
 
contaminating protein, larger loads of target protein are needed, or alternatively sized 
exclusion columns with smaller bed volumes. 
5.1.5 Freeze-thaw degradation of purified fractions 
The Kunitz protease inhibitor domain present within the larger isoforms of APP is 
known to be an inhibitor of trypsin-like serine proteases. Protease inhibitors were 
required as APP695 lacks this domain and is therefore potentially subject to 
degradation extracellularly (Caswell et al., 1999). Despite using both PMSF, a broad 
spectrum serine protease inhibitor, and EDTA, a broad spectrum metalloproteinase 
inhibitor, purified fractions still contained fragments of EGFPsAPP variants in some 
preparations as detected by colloidal Coomassie staining and Western analysis. This 
was likely to have occurred during freeze/thaw cycles of aliquots of the purified 
fractions. For future research it would be wise to store single use aliquots at -80C0 and 
use accordingly. 
5.1.6 Non-linear quantification using HRP-conjugated secondary antibodies 
EGFPsAPP variants were quantified against known standards using Western 
immunoblotting, 20 antibodies conjugated to perioxidases and ECL reagent. This is a 
simple method to give approximate EGFPsAPP variant concentrations with very little 
sample required. This method of quantification is approximate as previous studies 
have found that the signal produced from ECL detection does not increase linearly 
with an increase in antibody binding (Schutz-Geschwender et al., 2004). In this study 
several concentrations of sAPPα were used as standards to compensate for this. In 
using infra-red (IR) fluorophore conjugated secondary antibodies Schutz-
Geschwender et al (2004) achieved higher sensitivity, a wide quantitative linear range, 
and low blot-to-blot signal variation. Using 20 antibodies conjugated to IR 
fluorophores would allow for more accurate quantification of EGFPsAPP variants 
while still requiring small amounts of sample. 
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5.2 Functional validation of EGFPsAPPα 
Prior to an analysis of membrane binding, EGFPsAPPα had to be functionally 
validated for retention of sAPPα function. This study aimed to determine whether its 
neuroprotective and LTP enhancing properties were still intact. sAPPα 
neuroprotection has previously been observed as increased viability in glucose 
deprived neuroblastoma cells (Turner et al., 2007), while sAPPα mediated 
enhancements of LTP has also been described in vivo in rats (Taylor et al., 2008). These 
studies allow sAPPα to be used as a positive control in which EGFPsAPPα can be 
compared against. 
5.2.1 Failure of viability assays to detect consistent EGFPsAPPα neuroprotection 
Surprisingly EGFPsAPPα was unable to be functionally validated with the previously 
successful MTT assay. Although considered the gold standard of viability assays, the 
MTT assay has a number of limitations. The assay is highly variable when detecting 
changes in cell number over a linear range, showed inconsistent derived 50% 
inhibitory concentration (IC50) of glycolysis inhibitors (van Tonder et al., 2015), and 
tetrazolium salt readily reacts with compounds that contain oxido-reductive potential 
(S. Wang, Yu, & Wickliffe, 2011). Very little is known about the structure and function 
of sAPPα. If sAPPα contains oxido-reductive potential it may reduce tetrazolium salt 
and overestimate the proteins neuroprotective effect against glucose deprivation. 
Although the resazurin assay is now recommended instead of the MTT assay due to 
more accurate measurements of IC50 values (van Tonder et al., 2015), the fluorescent 
product, resorufin, can also be further reduced into the nonfluorescent 
hydroresorufin. This extra reduction step occurs if resazurin is incubated for an 
extended period of time or is applied to cell cultures at low concentrations (O'Brien et 
al., 2000). 
The insult caused by glucose deprivation can be too severe to be rescued by sAPPα or 
EGFPsAPPα and so has to be carefully optimised. Alternative stress inducing 
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conditions to create viability loss in SH-SY5Y cells would be valuable. SH-SY5Y cells 
can survive prolonged anoxia but in conjunction with glucose deprivation cells have 
a 54% viability loss after 32h (Fordel et al., 2007). This suggests that anoxia alone may 
be able to induce an insult that is large enough to cause a viability loss, but small 
enough to be rescued by sAPPα and EGFPsAPPα. Other forms of nutrition restriction 
and environmental condition alterations have been investigated for their detrimental 
effects on cell viability. These include pH modifications (Eagle, 1973), amino acid 
starvation (Mizushima et al., 2004) and the most relevant, amyloidβ induced cell death 
(Boldyrev et al., 2004). As Aβ is thought to be involved in Alzheimer’s related cell 
death and also does not encourage the production of reactive oxygen species (ROS), it 
could be an ideal candidate as the insult agent used in viability assays that measure 
reduced colourmetric or fluorometric products. 
The SH-SY5Y cells used in these studies were not differentiated into human neuronal-
like cells. Differentiation of SH-SY5Y cells is a lengthy procedure but may increase 
their susceptibility to sAPPα and EGFPsAPPα mediated neuroprotection, as 
differentiated SH-SY5Y have been shown to be neurotrophic factor-dependent 
(Encinas et al., 2000). Neuron-specific proteins are rarely expressed or distributed in 
undifferentiated cells and is therefore not an ideal in vitro model of a mature neuron 
(Agholme et al., 2010). Upon differentiation with a number of factors including brain 
derived neurotrophic factor, neuregulin β1, nerve growth factor and vitamin D3, cells 
differentiate into sustainable cells with resemblances to mature neurons. Moreover, 
differentiated cells express tau-phosphorylation, making them a good model for AD 
(Jämsä et al., 2004). Use of primary neuronal cultures, which are already sensitized to 
neurotropic factors, could be used as an alternative approach to using differentiated 
SH-SY5Y cell lines in the above-mentioned neuroprotective assays (Ambacher et al., 
2012; Barde., 1989; Sofroniew et al., 2001). 
While inconsistent, the resazurin assay displayed significant neuroprotection in 
glucose and FCS deprived SH-SY5Y cells when 10 nM EGFPsAPPα was applied. This 
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indicates EGFPsAPPα has likely retained its neuroprotective capacity, however as 
sAPPα, the positive control, failed to demonstrate neuroprotection more robust 
methods of functional validation were required. 
5.2.3 Conjugating EGFP to the N-terminus of sAPPα does not perturb LTP-inducing 
properties 
sAPPα knock-in has been shown to restore electrophysiological abnormalities in APP-
deficient mice (Ring et al., 2007). Application of 1nM sAPPα also elicits an increase in 
LTP in rat hippocampal sections (Taylor et al., 2008). Here I demonstrated that 
EGFPsAPPα is able to evoke a quantitatively similar increase in LTP compared to 
sAPPα in rat hippocampal slices. Jodi Morrissey assisted with this study as she has 
expertise to carry out the electrophysiology. This implies that conjugating EGFP to the 
N-terminus does not disrupt its role in mediating neuroplasticity. 
sAPPα-mediated neurite outgrowth has been shown to require activation of 
NMDARs and MAPK/ERK recruitment (Gakhar‐Koppole et al., 2008). Real time PCR 
and immunocytochemistry has also shown that sAPPα and sAPPβ stimulates Egr1 
expression downstream of MAPK/ERK activation (Chasseigneaux et al., 2011). 
Interestingly, a previous study reported that Egr1 -/- mice show a deficit in LTP (Jones 
et al., 2001). One could therefore hypothesise that sAPPα-mediated LTP requires the 
presence of Egr1 and therefore receptor mediated MAPK/ERK signalling. Enhanced 
phosphorylation of these kinases may therefore indicate for EGFPsAPPα receptor-
mediated cell signalling and thereby can be used as an alternative method of 
functional validation. 
5.3 Does EGFPsAPPα bind to the plasma membrane? 
If induction of LTP and other sAPPα mediated functions is a direct result of interaction 
between sAPPα and a receptor, and EGFPsAPPα has retained LTP-inducing 
properties, then membrane binding of EGFPsAPPα should be detectable by 
fluorescence measuring techniques. 
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5.3.1 Flow cytometry fails to detect EGFPsAPPα binding in the presence or absence of 
heparin 
Flow cytometry failed to detect GFP fluorescence in SH-SY5Y cells incubated in 10nM 
EGFPsAPPα. Previous literature suggests a minimal GFP concentration of about 100 
nM is needed, 10 times higher than the concentration used in this study, therefore it 
was perhaps not surprising that EGFPsAPPα binding membrane binding and 
internalisation could not be detected. This equates to about 10,000 intracellular or 
2,000 extracellular EGFP molecules (Wulff et al., 2006). 
5.3.2 Standard fluorescence microscopy lacks sensitivity to detect EGFPsAPPα 
binding 
Standard fluorescence microscopy was able to detect fluorescence from expressed 
EGFPsAPP variants in HEK293T stable cell lines, but could not detect up to 75 nM 
applied EGFPsAPPα in SY-SY5Y cells. This suggests that standard fluorescent 
microscopy alone is not sensitive enough to detect whether EGFPsAPPα is initiating 
it’s signalling via PM binding/internalisation.  
The detection limit for standard fluorescence microscopy of cytosolic GFP has been 
found to be approximately 1 μM, however lower levels may be detectible if there are 
high local concentrations and GFP is targeted to discrete subcellular compartments 
(Niswender et al., 1995). Although the EGFPsAPPα visualised on the PM may be more 
easily detectible than cytosolic EGFPsAPPα, the applied concentration of EGFPsAPPα 
is at least 13 fold smaller than the suggested cytosolic detection limit. However, 
enhanced exposure of EGFPsAPPα applied SH-SY5Y cells suggested that binding was 
occurring as early from 2 min after-application of 20 nM EGFPsAPPα. 
5.3.3 Low immunocytochemistry sensitivity and ways to improve signal 
Immunocytochemistry was used as an attempt to increase the signal of EGFPsAPPα 
PM binding. Despite an increased signal as shown with the EGFPsAPPα expressing 
HEK293T cell line, purified EGFPsAPPα applied to SH-SY5Y cultured cells could not 
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be detected on or within the cell by this method. This is surprising as enhanced 
exposure of EGFPsAPPα applied SH-SY5Y cells suggested towards EGFPsAPPα cell 
surface binding. Nevertheless, this may indicate binding is transient perhaps because 
of EGFPsAPPα-receptor internalisation. 
A variety of techniques have been developed in which the sensitivity of 
immunocytochemistry can be increased. Most laboratories frequently fix slices/cells 
with some variant of formaldehyde. Cells or tissues fixed with formalins tend to stain 
weakly or fail to stain at all (McNicol & Richmond, 1998). This is a common 
phenomenon known as epitope masking. There are multiple strategies in which 
scientists can alleviate from this issue occurring, these being antigen retrieval or signal 
amplification. 
Fixation can modify the structure of proteins so that target epitopes cannot be detected 
by a specific antibody. Antigen retrieval is a process where these epitopes are 
recovered by reversing structural changes caused by fixation (J. Ramos-Vara & Miller, 
2014). Eighty percent of formalin fixed tissue/cells require a form of antigen retrieval 
in order to optimise binding of antibody to antigen (J. A. Ramos-Vara & Beissenherz, 
2000). This could provide a possible reason as to why externally bound EGFPsAPPα 
was difficult to detect through ICC in paraformaldehyde fixed SY-SH5Y cells. The two 
most common antigen retrieval practises utilise protease degradation (Battifora & 
Kopinski, 1986) or heat based retrieval (Shi, Key, & Kalra, 1991).  
Alternative methods aim to increase the sensitivity of target antigens. Avidin-biotin 
complexes conjugated to horse-radish perioxidase (HRP) have been used for decades 
in order to detect low-level expressing proteins (Hsu, Raine, & Fanger, 1981). 
Tyramide signal amplification takes advantage of the high affinity between HRP and 
tyramide. Tyramide is readily converted by HRP into a highly reactive oxidised 
intermediate and binds to any tyrosine residues in close proximity. If conjugated to a 
fluorophore, tyramide has the ability to increase the immunofluorescent signal by at 
least 8 fold (Ness et al., 2003; Schönhuber et al., 1997; Toda et al., 1999). In using both 
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antigen retrieval plus signal amplification techniques the likelihood for detection of 
EGFPsAPPα binding could have been substantially increased. The EGFPsAPPα 
within expressing cells was clearly detected, however. 
5.3.4 TIRFM successfully displays EGFPsAPPα binding 
Initial TIRF analysis of SH-SY5Y membranes displayed a large background of intrinsic 
fluorescence. This background fluorescence was persistent despite using Gibco® 
FluoroBriteTM DMEM, a DMEM-based formula with 90% lower background 
fluorescence than standard phenol red-free DMEM. Utilisation of alternative cell lines 
(CHO & NT2) and washing cells with PBS prior to visualisation also failed to remove 
background fluorescence (data not shown). 
Many papers have described the limits of single molecule localisation uncertainty 
with an increase in noise signal (Betzig et al., 2006; Ober, Ram, & Ward, 2004; Stallinga 
& Rieger, 2012). Unlike the aforementioned studies, the current study did not have 
access to automatic tracking software, thus stacked images produced from TIRFM 
could only be analysed with a manual tracking ImageJ plugin (Cordelières). 
Manual tracking algorithms can be divided into two main categories. The first 
category estimates the exact point of a target molecule in each frame. The second 
category estimates the change in position of a particle based on its location in the 
previous frame. The manual tracking ImageJ plugin used in this study matches the 
centroid algorithm, an algorithm belonging to the first category (Cheezum, Walker, & 
Guilford, 2001). This algorithm measures the centre of mass of the pixels within a 
signal box. In order for this algorithm to function correctly the background must be 
removed. 
TIRFM using manual tracking analysis was able to visualise single molecules of 
EGFPsAPPα binding to SH-SY5Y membranes, however there were difficulties during 
the analysis stage. Occasionally the targeted EGFPsAPPα molecule would drop out 
from the visual plane of focus, disappearing for a few frames before reappearing. This 
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in conjunction with a low signal-to-noise ratio made the analysis particularly 
cumbersome and time-consuming. Cheezum et al., (2001) quantitatively compared the 
centroid against other commonly used tracking algorithms and found that a direct 
Gaussian fit algorithm is the most robust at tracking single fluorophores during low 
signal-to-noise experiments. 
Nevertheless, this study is the first to describe the detection of EGFPsAPPα binding 
to SH-SY5Y membranes and strongly suggests that there is at least a transient 
interaction with a receptor or heterodimisation with APP/APLP. sAPPα-membrane 
binding has been described in FRTL-5, B104 and PC12 cells, however binding has not 
previously been analyzed in real time (Hoffmann et al., 1999). Furthermore, FRTL-5 
and PC12 cells are derived from thryoid and adrenal tissue respectively, therefore not 
ideal candidates for models of neuronal cell lines 
sAPPα’s first two heparin binding domains, one within the GFLD and the other 
contains of the RERMS sequence, have been implemented in binding membrane 
bound heparin sulphate proteo-glycans. If membrane binding is reliant on these 
regions, then substituting residues within these regions should perturb sAPPα 
membrane binding and signal transduction. The isolated Ac-RER palindromic peptide 
provides significant neuroprotection against glucose depriviation in SH-SY5Y cells, 
whereas the neutral AAA control peptide does not provide neuroprotection and in 
fact displays a non-significant neurotoxic trend (Morris, 2011). This highlights the 
importance of the RER peptide in neuroprotection and therefore the lack of it in sAPPα 
RER328AAA may have major impacts on the protein’s membrane binding capacity 
and neuroprotective signal transduction. 
Cis-heterodimerisation could also occur across these heparin binding domains 
(HBDs), suggesting that sAPPα can bind with APP at the membrane (Baumkötter et 
al., 2014). As mentioned above, this interaction may be perturbed with substitution of 
the RER tripeptide motif. Extracellular heparin sulfates may also be able to compete 
with these HBDs to interupt dimerisation. 




This study has described a method in which FACS can enrich stable recombinant cell 
populations with low abundances of cells expressing fluorescently tagged proteins. 
Concentrated EGFPsAPP media was purified with a one-step heparin binding FPLC 
protocol, a method that has previously been used to purify sAPPα. This confirms that 
conjugating EGFP to the N-terminus of sAPPα does not disrupt the multiple HBDs 
located throughout the protein. Although inconsistent in replicate experiments, 10 nM 
EGFPsAPPα displayed significant neuroprotection from glucose and FCS deprivation 
in SH-SY5Y cells. Electrophysiological studies of EGFPsAPPα treated rat hippocampal 
slices demonstrated further functional integrity of the protein, as EGFPsAPPα could 
elicit enhancement of LTP by a similar amount to sAPPα. Fluorescence microscopy of 
EGFPsAPPα applied SH-SY5Y cultures displayed an incremental increase in binding 
with time. Lastly, SH-SY5Y membrane binding of EGFPsAPPα was visualised using 
manual tracking software in conjunction with TIRFM. 
5.5 Future directions 
Although heparin binding capacity was retained in purified EGFPsAPPβ and the 
EGFPsAPPα variants Δ602-612, Δ608-612, K612A and RER328AAA, these proteins 
remain to be tested for further functional validation as heparin binding capabilities do 
not provide strong enough evidence for functional integrity. Unless a more robust 
viability assay is found the untested variants could be functionally validated through 
measurement of LTP induction in rat hippocampal slices. The only limitation in using 
electrophysiology as the sole form of functional validation is that a selected 
EGFPsAPP variant may already have impaired LTP enhancement, therefore novel 
robust forms of validation will be required in future experiments.  
As the structure of full-length sAPPα is currently unknown, it is impossible to 
determine whether EGFPsAPPα is folded correctly. Therefore, efforts should be 
invested into determining the crystal structure of sAPPα or to perform 
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homologymodelling. Although TIRFM hinted towards EGFPsAPPα cell surface 
binding, the evidence was not definitive. It may be possible to detect 
binding/internalization of EGFPsAPPα by fixing EGFPsAPPα treated cells, separating 
specific cellular compartments from each other and then performing Western 
immunoanalysis. 
There is a distinct lack of evidence for binding partners and cell surface receptors in 
with which sAPPα interacts. Discovering a specific receptor will reinforce the 
proposal that sAPPα binding to plasma membranes initiates cell signalling. Members 
of our lab are currently searching for sAPPα binding partners to better understand 
how sAPPα initiates its signalling. This is being achieved through a photo-cross-
linking label transfer strategy, where Sulfo-SBED-conjugated sAPPα (bait) transfers a 
biotin label to the interacting partner (prey). Here the prey can be streptavidin affinity 
purified and identified via mass spectrometry.  
Once the interacting partners are identified, siRNA knockdown of these receptors in 
EGFPsAPPα applied SH-SY5Y or primary neuronal cultures could be used to validate 
interaction. If binding still occurs, then this suggests there are more than one specific 
receptor. Mutation of specific regions within sAPPα may highlight whether these 
regions are involved in interacting with putative binding partners. Furthermore, 
interaction between EGFPsAPPα and putative, halo-tagged (Los et al., 2008) 
membrane-bound receptors could be possible via Förster radiance energy transfer 
under TIRFM.  
Signalling of sAPPα could occur through multiple means, however whether this is cell 
surface receptor mediated signalling or whether it is due to sAPPα internalisation is 
uncertain. Activation of the MAPK/ERK pathway implies for receptor mediated 
signalling. However, trans-homodimerisation between sAPPα and APP may lead to 
internalisation of the entire complex. If so, then in using ICC it may be possible to co-
localise sAPPα with specific subcellular markers.  
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sAPPα is found associated with BACE1 in brain tissue extracts and may modulate 
APP processing towards the non-amyloidogenic pathway (Obregon et al., 2012). As 
previously noted, BACE1 works optimally in low pH conditions and so interactions 
with sAPPα may occur in the late endosome/lysosomal compartments (Vassar et al., 
1999). Upon tagging sAPPα with pHluorin, a pH-sensitive GFP, it may possible to 
detect a change in fluorescence with transport to these subcellular compartments, as 
well as co-localisation with BACE1 (Mahon, 2011). 
5.6 Final note 
This study is but a small part of the overarching aim to understand AD 
pathophysiology and to develop an effective therapeutic agent to counter this 
destructive disease. Considering that AD produces a large global economic burden 
and that the number of cases is expected to increase exponentially, it highlights the 
urgency to develop therapeutic agents. sAPPα promotes a number of positive 
outcomes that can already be mimicked by small peptide derivatives, that have 
promise as a peptidomimetic. This study has shown that EGFPsAPPα is produced by 
conventional purification protocols in which sAPPα is able to be purified, that it can 
mimic sAPPα’s effects of eliciting LTP and that it binds to the cell surface of 
neuroblastoma cells. These results further support the current theory in which sAPPα 
acts as ligand to membrane-bound receptors, but whether the protein is then rapidly 
internalised and stimulates its beneficial properties intracellularly is still uncertain. 
The difficulty in detecting significant membrane bound sAPPα may support for rapid 
internalisation. 
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All chemicals used were of analytical grade. All solutions were prepared with Milli-
Q® ultrapure H2O. Where necessary, solutions were either sterilised by autoclaving at 
121oC for 20 min at 15 psi or filtered through a 0.22 μm filter. The following is a list of 
specialised materials:
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Amersham Biosciences, Sweden: 
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AppliChem GmbH, Germany:  
Agarose, HEPES, N, N, N’, N’ – 
tetramethyl-ethylenediamine 
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disposable 0.22μm filter, 10 mL, 50 mL 




50 mL centrifuge tube 
Bio-Rad Laboratories incorporation, 
Acrylamide/Bis solution 37.5:1, Broad 
Range SDS-PAGE molecular weight 
standards, ECLTM Western Blotting 
Detection Reagents
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BDH Chemicals, England: 
Ammonium persulphate, SDS, Triton-
X100 
Corning Incorporated, USA: 
12 well cell culture cluster, 96 well cell 
culture cluster 
GE Healthcare, UK: 
Superdex 200 10/300 GL column 
Gibco®, USA (Invitrogen Corporation): 
Anti/Anti solution, Dulbecco’s 
Modified Eagle Medium (DMEM) 
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15mL CELLSTAR® polypropylene 
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Invitrogen Corporation, USA: 
Ethidium bromide, Goat anti-Rabbit 




Koch-Light Limited, UK: 
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Life Technologies, USA 
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Licor, USA 
IRDye 680RD anti-rabbit, IRDye 
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Menzel Glazer, Germany: 
18mm glass coverslips 
MilliporeTM-, USA: 
Millicell culture plate inserts 
Molecular Probes, USA: 
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Oxoid Limited, UK: 
Phosphate buffered saline tablets 
(Dulbecco A) 
Pams, New Zealand: 
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Parnell Technologies Pty Ltd: 
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Peptides International, USA: 
TAPI-1 
Qiagen, Germany: 
Qiaprep® Spin Miniprep Kit 
Roche, Switzerland: 
cOmplete protease inhibitor 
Roche Applied Science, Germany: 
λDNA, restriction endonucleases (Eco 
RI & HindIII) and the respective buffer 
(Buffer B), X-treme gene 9 DNA 
transfection reagent, 
Scharlau Chemie S.A., Spain: 
Ethylenediaminetetraacetic acid 
(EDTA), hydrochloric acid, 
isopropanol 
Schleicher & Scheull, Germany: 
Protran® nitrocellulose membrane
Sigma-Aldrich Incorporation, USA: 
Anti-Amyloid Precursor Protein, N-
Terminal antibody produced in rabbit, 
Anti-rabbit IgG (whole molecule) 
peroxidase conjugate produced in goat, 
BCA reagents, β-mercaptoethanol, 
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Weber Scientific, NZ 
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Whatman Limited, UK: 
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Solutions for cell culture 
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Adjusted to pH 7 with NaOH 
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Ham’s F-12K (Kaighn’s) medium 89% 
(v/v) 
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PenStrep 1% (v/v) 
DMEM+ 
DMEM 89% (v/v) 
FBS 10% (v/v) 
PenStrep 1% (v/v) 
DMEM- 
DMEM 99% (v/v) 
PenStrep 1% (v/v) 
Freezing medium 
90% FBS (v/v) 
10% DMSO (v/v) 
PBS, 1x 
Dissolved 1 table in 100mL milliQ H2O
SH-SY5Y culture medium 
Ham’s F-12K (Kaighn’s) Medium 
44.5% (v/v) 
Minimal Essential Media α (MEMα) 
44.5% (v/v) 
FBS 10% (v/v) 
PenStrep 1% (v/v) 
 
Solutions for DNA analysis 
1% Agarose Gel 
TBE Buffer, 0.5x 
Agarose 3% (w/v) 
Ethidium bromide 0.1% (v/v) 
DNA loading buffer, 10x 
50% (w/v) sucrose 
0.1% (w/v) bromophenol blue 
7 M urea 
0.1mM EDTA 
Adjusted to pH 8 
TBE Buffer, 10x 
900 mM Tris 
20 mM EDTA 
5.5 % (w/v) boric acid 
pH was not adjusted
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Solutions for protein analysis 
Affinity chromatography elution buffer, 1x 
20 mM Tris 
2 M NaCl 
1 mM PMSF 
1 mM EDTA 
Colloidal Coomassie blue stain 
10% (w/v) ammonium sulphate 
0.1% (w/v) brilliant blue G 
20% (v/v) ethanol 
3% (v/v) ortho-phosphoric acid 
Cracking buffer, 3x 
150 mM Trip pH 6.8 
6% (w/v) SDS 
8 M urea 
0.3% (w/v) bromophenol blue 
Desalting Buffer, 1x 
20 mM Tris 
1 mM PMSF 
1 mM EDTA 
Adjusted to pH 7 with HCl, filter 
sterilised and degassed
Destaining solution 
5% (v/v) methanol 
7.5% (v/v) acetic acid 
Inner running buffer, 10x 
3% (w/v) Tris 
14% (w/v) Glycine 
0.8% (w/v) SDS 
Outer running buffer, 1x 
0.3 % (w/v) Tris 
1.4% (w/v) Glycine 
PBS (phosphate buffered saline), 1x 
Dissolved 1 tablet in 100 mL 
ddH2OPBS Tween®-20, 1x, pH 7.4 
80 mM di-sodium hydrogen 
orthophosphate anhydrous 
20 mM sodium di-hydrogen 
orthophosphate anhydrous 
100 mM sodium chloride 
0.1% (v/v) Tween® 20
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Ponceau S stain 
0.1% (w/v) Ponceau S 
5% (v/v) acetic acid 
SDS polyacrylamide resolving gel, 10% 
1 x Separating gel buffer 
9.8% (v/v) acrylamide:bisacrylamide 
(27.5:1) 
0.09% (w/v) ammonium persulfate 
0.075% (v/v) TEMED 
SDS polyacrylamide stacking gel, 10% 
1 x Stacking gel buffer 
9.4% (v/v) acrylamide:bisacrylamide 
(37.5:1) 
0.045% (w/v) ammonium persulfate 
0.02% (v/v) TEMED
Separating gel buffer, 4x 
36% (w/v) Tris 
0.4% (w/v) SDS 
pH was adjusted to 8.8 with HCl 
Stacking gel buffer, 4x 
6% (w/v) Tris 
0.4 % (w/v) SDS 
pH was adjusted to 6.8 with HCl 
Transfer buffer, 1x 
25 mM Tris 
1 mM PMSF 
1 mM EDTA 
Adjusted to pH 7 with HCl, filter 
sterilised and degassed 
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Appendix II: Cell viability assays 
Sample of fluorescence intensity readings obtained when performing a resazurin cell viability assay with freeze/thawed resazurin 
aliquots. Outliers were identified and removed with a ROUT test. 
Freeze/thawing of resazurin aliquots leads to degradation of the sample and a 
decrease in fluorescence intensity 
P13 Once reaching optimal confluency (80%) cells were pre-incubated with TAPI-1 (50 μM) for 24 
h and throughout the duration glucose deprivation. SH-SY5Y were pre-incubated with sAPPα (1 
nM and 10 nM) and EGFPsAPPα (1 nM and 10 nM) 2 h prior to and during glucose deprivation. 
SH-SY5Y cell viability was assessed by cell metabolism of resazurin following 5 h of glucose 
deprivation. Metabolism of resazurin was allowed to occur for 3 h. Positive control – SH-SY5Y 
cells supplemented with glucose. Negative control – SH-SY5Y deprived and glucose and treated 
with 1 x PBS (vehicle). n = 10. Error bars = SD. *p < 0.05 (One-way ANOVA, Dunnett’s multiple 
comparison test). Outliers removed with a ROUT (Q = 10.00%) test. 
Treatments Fluorescence intensity Average SD 
Glucose present 1968 2719 2953 2735 2732 2075 2317 2902 2951 2189 2554 378.9 
Glucose deficient 3306 2340 2624 2852 3270 3402 1862 3849 2030 2633 2816 639.7 
1nM sAPPα 2440 3386 2880 1428 2217 2774 2828 3643 3248 2452 2729 640 
10nM sAPPα 2649 2454 2517 2700 2210 2604 2172 2480 2173   2319 427.7 
1nM EGFPsAPPα 2170 3136 1837 2166 2201 2489 2029 2505 3237 1825 2359 491.9 
10nM EGFPsAPPα 3034 2298 2889 3192 2565 2442 2928 1759 3303 2174 2658 494 
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Appendix III: Conventional fluorescence microscopy 
Membrane binding was not detected in short-length EGFPsAPPα incubated SH-SY5Y cells 
P13 SH-SY5Y cells were seeded at 5 x 105 cells/mL in a 24 well plate and allowed to grow for 24 h prior to drug treatment. Positive control = HEK293T 
EGFPsAPPα stable cell line. sAPPα= SH-SY5Y cells incubated with 20nM sAPPα. Other conditions indicate how long SH-SY5Y cells were incubated in 20nM 
EGFPsAPPα. Cells were visualised under bright field (top panels) or for EGFP fluorescence (bottom panels). 
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EGFPsAPPα binding was not aided in the presence of heparin 
P 12 cells were seeded at 5 x 105 cells/mL in a 24 well plate and were allowed to grow for 24 h prior to drug treatments. HEK293T EGFPsAPPα = HEK239T cells 
stably expression EGFPsAPPα. sAPPα = SH-SY5Y cells incubated with 20nM sAPPα for 10 min. Following a 10 min EGFPsAPPα incubation (1 nM or 10 nM as 
indicated) SH-SY5Y cells were washed with 5 U/mL heparin containing 1 x PBS. Cells were visualised under bright field (top panels) or for EGFP fluorescence 
(bottom panels). As sAPPα has been show to bind HSPGs, heparin may competitively interfere with this interaction. Conversely, if heparin aids in sAPPα 
trans-dimerisation with APP then this will encourage interaction and therefore membrane binding. 
  
   
 
140 
TAPI-1 inhibition of endogenously expressed sAPPα fails to increase the detection of EGFPsAPPα cell surface binding 
SH-SY5Y cells were seeded at 5 x 105 cells/mL in a 24 well plate and were treated with TAPI-1 for 24 h to remove endogenous sAPPα production. 20nM of 
EGFPsAPPα was then applied to SH-SY5Y for the specified times and visualised under bright field (top panels) or for EGFP fluorescence (bottom panels). –ve 
= SH-SY5Y cells without application of EGFPsAPPα. SH-SY5Y cells were treated with EGFPsAPPα for the indicated times.
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EGFPsAPPα cell surface binding is undetectable in HEK293T cells 
HEK293T cells were seeded at 5 x 105 cells/mL in a 24 h plate and were grown for 24 h prior to drug treatment. HEK293T cells were then treated with EGFPsAPPα (20 
nM) for the indicated times and visualized under bright field (top panels) or for EGFP fluorescence (bottom panels). Negative control = HEK293T cells not treated 
with EGFPsAPPα. 
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Appendix IV: TIRFM 
Figure 4.14 – Endogenous fluorescence in SH-SY5Y cells during TIRFM 
Circular glass coverslips (18 mm; Menzel) were flame sterilised and placed in a 6 well plate under cell 
culture conditions. P10 SH-SY5Y cells were seeded at 5 x 105 cells/mL into these wells and grown for 24 
h. (A): SH-SY5Y cells under bright field. (B): Background fluorescence of SH-SY5Y cells under TIRFM. 
(C): Growth media only under TIRFM. (D): PBS only under TIRFM. 
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Attached is a DVD containing two .avi files: 
TIRF only.avi – Video of TIRF experiment used for Figure 4.15 
Overlay Dots & Lines.avi – Video of TIRF only.avi with dots & lines overlaid on 
manually tracked EGFPsAPPα molecules. 
 
